CA2168560C - Substituted oxazine and thiazine oxazolidinone antimicrobials - Google Patents
Substituted oxazine and thiazine oxazolidinone antimicrobials Download PDFInfo
- Publication number
- CA2168560C CA2168560C CA002168560A CA2168560A CA2168560C CA 2168560 C CA2168560 C CA 2168560C CA 002168560 A CA002168560 A CA 002168560A CA 2168560 A CA2168560 A CA 2168560A CA 2168560 C CA2168560 C CA 2168560C
- Authority
- CA
- Canada
- Prior art keywords
- fluoro
- methyl
- oxo
- oxazolidinyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A compound of structural formula (I) or pharmaceutically acceptable salts thereof wherein: X is O, S, SO, SO2, SNR10 or S(O)NR10; R is (a) hydrogen, (b) C1-C8 alkyl optionally substituted with one or mole of the following. F, Cl, hydroxy, C1-C8alkoxy, C1-C8acyloxy or -O-CH2-Ph, (c) C3-C6cycloalkyl, (d) amino, (e) C1-C8alkylamino, (f) C1-C8dialkylamino or (g) C1-C8alkoxy; R1 is H, except when X is O, then R1 can be H, CH3, CN, CO2H, CO2R or (CH2)m R11 (m is 1 or 2); R2 is independently H, F or Cl; R3 is H
except when X is O and R1 is CH3, then R3 can be H or CH3; R10 is independently H, C1-C4alkyl (optionally substituted with chloro, fluoro, hydroxy, C1-C8alkoxy, amino, C1-C8alkylamino, or C1-C8dialkylamino) or p-toluenesulfonyl; R11 is hydrogen, OH, OR, OCOR, NH2, NHCOR or N(R10)2; and n is 0, 1 or 2. The oxazine and thiazine oxazolidinone derivatives are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp..
except when X is O and R1 is CH3, then R3 can be H or CH3; R10 is independently H, C1-C4alkyl (optionally substituted with chloro, fluoro, hydroxy, C1-C8alkoxy, amino, C1-C8alkylamino, or C1-C8dialkylamino) or p-toluenesulfonyl; R11 is hydrogen, OH, OR, OCOR, NH2, NHCOR or N(R10)2; and n is 0, 1 or 2. The oxazine and thiazine oxazolidinone derivatives are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp..
Description
SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS
)background of the Invention The subject invention discloses oxazine and thiazine oxazolidinone derivatives. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, mycobacterium avium and Mycobacterium spp..
Information Disclosure The present compounds are similar to piperazine containing ring structures such as those disclosed in the publications below except that the distal nitrogen atom is replaced with an oxygen, sulfur, sulfinyl, sulfonyl, sulfimidoyl or sulfonimidoyl. The instant compounds are unique in that typically the unsubstituted piperazinyl oxazolidinone compounds have little useful antibacterial activity whereas the activity observed for the corresponding oxazine and thiazine derived oxazolidinones is high.
Publication W093/23384 discloses oxazolidinones containing a substituted diazine moiety and their uses as antimicrobials.
Publication W093/09103 discloses substituted aryl and heteroaryl-phenyl-oxazolidinones useful as antibacterial agents.
Publication W090/02744 discloses 5'indolinyl-S~i-amidomethyloxazolidinones, 3-(fused-ring substituted)phenyl-5(3-amidomethyloxazolidinones, and 3-(nitrogen substituted)phenyl-5(3-amidomethyloxazzolidinones which are useful as antibacterial agents.
Other references disclosing various oxazolidinones include U.S. Patent 4,801,600, 4,921,869, Gregory W.A., et al., J. Med. Chem., 32, 1673-81 (1989); Gregory W.A., et al. ,j~
Med. Chem., 33, 2569-78 (190); Wang C., et al., Tetrahedron, 45, 1323-26 (1989); and Brittelli, et al., J. Med. Chem., 35, 1156 (1992).
European Patent Publication 352,781 discloses phenyl and pyridyl substituted phenyl oxazolidinones.
European Patent Publication 316,594 discloses 3-substituted styryl oxazolidinones.
3 0 European Patent Publication 312,000 discloses phenylmethyl and pyridinylmethyl substituted phenyl oxazolidinones.
WO 95/07271 ~ ' PCT/LTS94/08904 Summary of the Invention In one aspect the subject invention is a compound of structural Formula I:
R
O
~ o X N N O H II
~N-C-R
~ 2 ) L~V/n or pharmaceutically acceptable salts thereof wherein:
X is O, S, SO, SO2, SNRl~ or S(O)NR10;
R is (a) hydrogen, (b) C1-C8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C1-C8 alkoxy, C1-C8 acyloxy or O-CH2-Ph, (c) C3-Cs cycloalkyl, (d) amino, (e) C1-C8 alkylamino, (f) C1-C8 dialkylamino, or (g) C1-Cg alkoxy;
Rl is H, except when X is O then Rl can be H, CH3, CN, C02H, C02R or (CH2)mRll (m is 1 or 2);
R2 is independently H, F or Cl;
R3 is H except when X is O and Rl is CH3 then R3 can be H or CH3;
Rl~ is independently H, C1-C4 alkyl (optionally substituted with chloro, fluoro, hydroxy, C1-C8 alkoxy, amino, C1-C8 alkylamino or C1-C8 dialkylamino) or p toluenesulfonyl;
Rll is hydrogen, OH, OR, OCOR, NH2, NHCOR or N(R1~)2; and nis0, lor2.
Preferred compounds where n is 0 are:
(a) (S)-N-[[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4-( 1-oxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]acetamide; or (d) (S~ N-[[3-[3-fluoro-4-(3-oxazolidinyl)JphenylJ-2-oxo-5-oxamlidinylJ
methyl] acetamide.
Preferred compounds where n is 1 are:
(a) (,S~ N-[[3-[3-fluoro-4-(4~hiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methylJ-acetamide;
(b) (S~ N-[[3-[3-fluoro-4-(1,1-dioxothiomorpholin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide;
(c) (S~ N-[[3-[3-fluoro-4-(1-oxothiomorpholin-4-yl)phenylJ-2-oxo-5-oxazolidinyl)methylJ-aceetamide; _ (d) (S') N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phenyl)-2~xo-S~xazolidinyl)methylJ-acetamide;
(e) (,S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2~xo-5-oxazolidinyl]methyl]acetamide;
(f) (S~ N-[[3-[3-fluoro-4-[1-[(p-toluenesulfonyl)imino)thiomorpholin-4-yl]phenyl)-2-oxo-5 oxazolidinyl]methyl]acetami~;
(g) (S') N-[[3-[3-fluoro-4-(4-morpholinyl)JphenylJ-2-oxo-5-oxazolidinyl]methyl]-hydroxyacetamide;
(h) (S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]-formamide;
(i) (S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl)-2-oxo-5-oxaTOlidinyl]methyl]methyl-carbamate; or (j) (S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenylJ-2-oxo-5-oxazolidinyl]methyl)-dichloroacetamide;
Preferred com~2ound~ where n is 2 are:
(a) (S~-N-[[3-[3-fluoro-4~he~Cahydrothiazepin-4-yl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-acetamide;
(b) (S~ N-[[3-[3-fluoro-4-(1,1-dioxohexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinylJmethyl]acetamide;
(c) (S~ N-[[3-[3-fluoro-4-(1-oxohexahydrooxazepin-4-yl)]pl~nyl]-2-oxo-5-oxawlidinyl]methyl]acetamide; or (d) (,S~ N-[[3-[3-fluoro-4-(hexahydrothiazepin-4-yl)phenyl]-2~xo-5-oxazolidinyl)methyl]-acetamide.
In another aspect, the subject invention is directed toward a method for treating microbial infections in patients by administering to a patient in need thereof an effective amount of a compound of Formula I as described above. The compound can be administered in a pharmaceutical composition either orally, parenterally or topically. Preferably, the compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weightJday, more preferably, from about 3.0 to about 50 mg/kg of body weightJday.
Detailed Description of the Invention The present invention discloses oxazine and thiazine oxazolidinones of structural Formula I as defined above. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, particularly gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium dvium and Mycobacterium spp..
The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Ci-C~ defines the number of carbon atoms present from the integer "i" to the integer "j" inclusive. Thus, C1-C3 alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl; C1-C8 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomeric forms thereof.
The term C1-C8 alkylamino means an amino moiety (-NH-) containing one alkyl moiety having 1 to 8 carbon atoms. The term C1-C8 dialkylamino means an amino moiety containing two alkyl moieties having 1 to 8 carbon atoms, for example, propylamino and dipropylamino respectively. The C1-C8 alkyl or C1-C4 alkyl groups can be optionally substituted with chloro, fluoro, hydroxy, C1-C8 alkoxy, amino, C1-C8 alkylamino, C1-C8 dialkylamino or -O-CHZPh where "Ph" is phenyl. "Acyloxy"
are groups such as methylcarbamate, ethylcarbamate,etc. Such optionally substituted C1-C8 alkyl grnups can include 1-chloropropyl, 1-fluoropropyl 3-chloropropyl, 3-fluoro propyl, 1-hydroxy butyl, 2-hydroxy butyl, 1-methoxypropyl, 1-octyloxy propyl, 1-amino propyl, 1-aminooctyl, 1-butylaminopropyl, 1-dibutylamino-propyl and the like.
Pharmaceutically acceptable salts means acid addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, prnpionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like when a basic group is present. These salts may be in hydrated form.
The benzene ring, in addition to being unsubstituted, can be substituted with one or more halogen atoms in the series fluorine or chlorine. Thus, the R2 groups can be independently either hydrogen atoms or halogen atoms in a variety of substitution patterns.
The RZ substituents are preferably both fluorine and, more preferably, fluorine and H.
The preferred absolute configuration at C-5 of the oxazolidinone ring of compounds claimed in this invention is as represented in the structure of Formula I.
This absolute configuration is called (S) under the Cahn-Ingold-Prelog nomenclature system. It is this (S)-enantiomer which is antibacterially active. The racemic mixture is useful in the same way and for the same purpose as the pure (S)-enantiomer; the difference is that twice as much racemic material must be used to produce the same antibacterial effect. It will be apparent to one skilled in the art that appropriate modifications to the morpholine or thiomorpholine ring systems of compounds of Formula I, for example the incorporation of a second chiral center (Rl not H), will lead to diastereomers. These diastereomers, in racemic and enantiomerically enriched fortes, are also within the scope of the compounds of Formula I of the invention.
Optically pure material could be obtained either by resolution from a racemic mixture by selective crystallization of a diastereomeric salt from, for example, an intermediate amine with an appropriate optically active acid such as dibenzoyl tartrate or 10-camphorsulfonic acid, followed by treatment with base to afford the optically pure amine.
The preferred method of preparation of oxazolidinones of Formula I in enantiomerically pure form is depicted in Charts 1 and 2.
As shown in Chart 1, oxazines and thiazines such as thiazolidine (R1= H, X = S, n = 0), oxazolidine (Rl = H, X = O, n = 0), morpholine (Rl = H, X = O, n = 1), thiomorpholine (Rl = H, X = S, n = 1), a substituted morpholine (Rl not H, X =
O, n = 1), hexahydro-1,4-thiazepine (Rl = H, X = S, n = 2), hexahydro-1,4-oxazepine (R1= H, X = O, n = 2), or a substituted hexahydro-1,4-oxazepine (R1 not H, X =
O, n = 2) of structure 1 are reacted with a functionalized nitrobenzene 2 (Y =
halogen or trifluoromethanesulfonate) in the presence of a suitable base such as N,N
diiso-propylethylamine and in a suitable solvent such as acetonitrile, tetrahydrofuran (THF) or ethyl acetate at reflux temperature to provide the adducts 3. When necessary, the Rl sidechain of 1 is protected with a suitable protecting groups) such as a benzyl or other variants as described in Greene, T. W.; Wuts, P. G. M.
"Protective Groups in Organic Synthesis", 2nd ed.; John Wiley & Sons: New York ( 1991) which is removed later in the synthesis. When X = O, the nitrn group of 3 is WO 95/07271 ~ PCT/L1S94/08904 then reduced by hydrogenation in the presence of a suitable catalyst such as palladium on carbon (hydrngen supplied in the form of a gas or indirectly via ammonium formate) in a suitable solvent such as ethyl acetate, tetrahydrofuran, methanol and mixtures thereof. Alternatively, and preferably in the case where X = S, the vitro grnup of 3 can be reduced by the action of aqueous sodium hydrosulfite in tetrahydrofuran at ambient temperature to give the anilines 4.
The anilines 4 are then converted to their benzyl (R4 = CH2Ph) or methyl (R4 =
CH3) urethane derivatives b, employing standard Schotten-Baumann conditions or other variations known to one skilled in the art. The urethanes b are then deprotonated with a suitable base such as n-butyllithium or LiN(SiMe3 )2 in a suitable solvent such as tetrahydrofuran ("THF") and at a suitable temperature such as -78 to -40°C
to give a lithiated intermediate which is then treated with commercially available (-)-(R)-glycidyl butyrate. Warming to ambient temperature then directly affords the hydroxymethyl-substituted oxazolidinones 6 in enantiomerically enriched form.
Compound 6 is then converted to the corresponding mesylate 7 (R5 = methane-sulfonyl) or aryl sulfonate 7 (R5 = ArS02, for example p-toluenesulfonyl) by the action of, for example, methanesulfonyl chloride/pyridine or methanesulfonyl chloride/triethylamine/dichloromethane or p-toluenesulfonyl chloride/pyridine.
The resultant sulfonate derivative 7 is then reacted with an azide source such as sodium or potassium azide in an aprotic solvent such as N,N dimethylformamide (DMF) or 1-methyl-2-pyrrolidinone optionally in the presence of a catalyst such as 18-crown-6 at a temperature of 50-90 °C to afford the azide 8 (Rs = N3). The azide is then reduced by hydrogenation with palladium on carbon or a platinum catalyst in an appropriate solvent such as ethyl acetate or methanol to give the corresponding amine 8 (R6 = NH2). Alternatively, the azide can be reduced by treatment with a trivalent phosphorus compound such as triphenylphosphine in a suitable solvent such as tetrahydrofuran followed by the addition of water. Alternatively, the mesylate or aryl sulfonate can be displaced with potassium phthalimide in acetonitrile at reflux or other suitable solvent. The phthalimide 8 (Rs = phthalimide) is then deprotected by the addition of aqueous methyl amine in refluxing ethanol, to give the amine 8 (Rs = NH2). Alternatively, the amine 8 may be obtained directly frnm mesylate 7 by treatment with ammonium hydrnxide by refluxing in isopropanol or THF. The amine 8 is then acylated by reactions known to those skilled in the art to give oxazolidinones of structure 9. For example, the amine can be reacted with an acid chloride or anhydride in a basic solvent such as pyridine at a temperature ranging frnm -30 to 30 °C to prnvide the acylated compound 9 (R = optionally substituted alkyl). It will be apparent to one skilled in the art that other aryl groups within the scope of this invention can be readily appended to the amine 8 (Rs = NH2) by standard acylation techniques, for example, those highlighted in March, J. "Advanced Organic Chemistry", 3rd ed.; John Wiley &
Sons: New York, 1985; p 370-375, to give additional examples of 9. At this juncture, any appended protecting group on the Rl sidechain of the branched morpholine or hexahydrn-1,4-oxazepine congeners (X = G is removed, where applicable, employing appropriate conditions such as those noted in Greene, T. W.; Wuts, P. G. M., "Protective Groups in Organic Synthesis," 2nd ed.; John Wiley & Sons: New York (1991). The compounds of structure 9 represent examples of oxazine- and thiazine-substituted oxazolidinone antibacterial agents of Formula I, which are the subject of this invention.
As shown in Chart 2, the thiazolidine-containing or thiomorpholine-containing oxazolidinones 10 (and also the hexahydro-1,4-thiazepine-containing variants), themselves examples of antibacterial agents of Formula I, can be further elaborated to additional compounds of Formula I as shown in Chart 2.
Specifically, 10 can be oxidized to the corresponding sulfoxides 11 (X = sulfinyl) with sodium metaperiodate in a mixture of water and methanol. In addition, compounds 10 or 11 can be oxidized to the sulfones 12 (X = sulfonyl) by treatment with oxone or 4-methylmorpholine N-oxide and catalytic osmium tetroxide in aqueous acetone.
Sulfides 10 can also be converted to sulfilimines 13 (X = sulfimidoyl). For example, treatment of 10 with chloramine-T trihydrate in dichloromethane in the presence of a suitable phase transfer catalyst such as hexadecyltributyl- phosphonium bromide affords compounds 13 (Rl~ = p-toluenesulfonyl). Additional sulfilimines can be prepared by methods known to one skilled in the art, for example, those disclosed in Oae, S.; Furukawa, N. "Sulfilimines and Related Derivatives"; American Chemical Society: Washington, D.C., 1983. Sulfoximine derivatives 14 (X =
sulfonimidoyl) are also accessible by further elaboration of the sulfoxides 11 and sulfilimines 13.
Numerous methods and variations for these transformations are available: ( 1) Johnson, C. R., "Comprehensive Organic Chemistry"; Jones, N., ed.; Pergamon Press: Oxford, 1979; Vol. 3, Chapter 11.11, (2) Johnson, C. R., Aldrichimica Actd, 1985, 18, 3-4 and references cited therein, (3) Johnson, C. R.; Lavergne, O., J. Org.
Chem. 1989, 54, 986-988 and references cited therein, (4) Johnson, C. R.;
Rigau, J.
J., J. Org. Chem. 1968, 33, 4340-4343, and (5) Oae, S.; Furukawa, N., "Sulf'ilimines and Related Derivatives"; American Chemical Society: Washington, D.C., 1983;
p 297-317 and references cited therein. For example, oxidation of N-WO 95107271 ~ PCT/US94108904 _g_ tosylsulfilimines 13 (Rl~ = p-toluenesulfonyl) with aqueous sodium hypochlorite in a mixture of ethyl acetate and dichloromethane in the presence of tetrabutyl-ammonium bromide affords N tosylsulfoximines 14 (Rl~ = p-toluenesulfonyl). The tosyl group of 14 may be removed under acidic conditions, for example, with concentrated sulfuric acid, to give 14 (R1~ = H). Further alkylation, acylation, or sulfonylation of the sulfoximine nitrogen under selected conditions described in the above references then prnvides additional examples of the sulfoximines 14 which are also antibacterial agents of Formula I claimed in this invention.
Representative prncedures for converting the sulfoxides 11 into the sulfoximines 14 can be found in the references listed immediately above. For example, 11 can be reacted with O-(mesitylsulfonylhydroxylamine) in a suitable solvent such as dichloromethane, as described in Johnson, C. R. et al., J. Org. Chem. 1974, 39, 2458-2459, to furnish the corresponding sulfoximines 14 (R1~ = H). Functionalization of the sulfoximine nitrogen as described above affords additional examples of 14. Alternatively, 11 can be reacted with p-toluenesulfonyl azide in the presence of a suitable promoter such as R,aney copper and in a suitable solvent such as methanol or methanol/dichloro-methane, as described in Johnson, C. R. et dl., J. Am. Chem Soc. 1973, 95, 4291, to provide the N tosylsulfoximines 14 (R1~ = p-toluenesulfonyl). As described above, the tosyl group may be removed and replaced with alternative groups to give additional examples of sulfoximines 14.
It will be apparent to those skilled in the art that the described synthetic procedures are merely representative in nature and that alternative conditions are known, for example, substituted morpholines where Rl is not equal to hydrogen:
Araki, K. et al. , poster presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 23-26, 1988, Los Angeles, CA, Abstract No. 947; and JP 03,291,274, JP 03,148,276, JP 03,066,688, JP
03,048,682, JP 02,019,380, JP 02,115,182, and EP 311,948. Synthesis of substituted hexahydro-1,4-oxazepine where Rl is not equal to hydrogen can be followed from Araki, K.
et al. , JP 02,115,181. For n is 0, see, Oh, Chang-Hyun et al., J.Antibiotics, 47:126-28 ( 1994).
These compounds are useful for treatment of microbial infections in humans and other warm blooded animals such as cattle by either parenteral, oral, or topical administration. An example, where the subject invention would be useful in cattle is in the treatment of mastitis.
The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formula I of this invention with a solid or liquid _g_ pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent.
Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or apprnpriate amounts of the active component, that is, the compound of Formula I according to this invention.
The quantity of active component, that is the compound of Formula I
according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound, the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
In therapeutic use for treating, or combatting bacterial infections in patients such as humans and other animals that can be diagnosed with bacterial infections, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 100 mg/kg, more preferably about 3.0 to about 50 mg/kg of body weightJday.
It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
The compounds of Formula I according to this invention are administered parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound according to Formula I as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to prnvide a suitably buffered isotonic solution, for example, having a pH of about 3.5-7. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents.
The compound according to Formula I generally will be dissolved in the carrier in an amount.sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage. The compounds of Formula I
according to this invention are advantageously administered orally in solid and liquid dosage forms.
As a topical treatment an effective amount of Formula I is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Preparation of such creams and gels is well known in the art and can include penetration enhancers.
Antimicrobial activity was tested in vivo using the Murine Assay procedure.
Groups of female mice (six mice of 18-20 grams each) were injected intraperitoneally with Staphylococcus dureus bacteria which were thawed just prior to use and suspended in brain heart infusion with 4% brewers yeast (Staphylococcus aureus) or brain heart infusion (Streptococcus species). Antibiotic treatment at six dose levels per drug was administered one hour and five hours after infection by either oral intubation or subcutaneous routes. Survival was observed daily for six days.
values based on mortality ratios were calculated using probit analysis. The subject compounds were compared against vancomycin as a control. The data are shown in Table 1.
Table 1 In Vivo Activity of Examples 1-5 Against S. aureus UC~ No. 9213 ED (mg/kg) Example No.
Example, PO Vancomycin, SC
1 1.25 3.9 2 2.0 2.3 3 3.4 2.5 4 5.5 2.0 6 5.6 3.9 8 12.4 2.0 9 4.4 2.0 10 6.8 5.0 11 14.0 2.0 Table 2 In Vitro Activity Against M. tb and M. avium MICA MIC'' MICA
COMPOUND M. tuberculosis M. avium M. avium EXAMPLE NO. 91-2225$ Lowell Young LPR
1 0.5 1.0 4.0 2 0.5 2.0 4.0 ISONIAZID~ <_0.015 Not done Not done AZIT ~OMYCI Not done 4.0 8.0 A The lowest concentration of drug required to kill the organism or inhibit its growth in vitro.
B Strain designation ~ Isoniazid is a control drug for the tuberculosis test and azithromycin is a control drug for the mycobacterium avium test.
The in vitro activity reported in Table 2 was conducted by standard dilution methods known to those skilled in the art. Briefly, serial two-fold dilutions of antibiotic are prepared in a diluent, and a standard volume of mycobacterial growth medium is added to drug aliquot. The medium is inoculated with a standardized mycobacterial cell suspension, and then incubated under appropriate conditions.
SUBSTITUTE SHEET (RULE 26~
PCT/US94l08904 WO 95/07271 2 ~ 6 s 5 6 0 Following incubation, the Minimal Inhibitory Concentration (MIC) is determined by visual observation. The MIC is defined as the lowest drug concentration (in pg/ml) required to inhibit mycobacterial growth.
Table 3 In vivo Antimycobacterial Activity COMPOUND Logy Colony-Forming EXAMPLE NO. Units of Mycobacterium tuberculosis Per Organ's Drug Treatment Spleen I Lung ~
NoneB 7.72 8.47 IsoniazidC 4.36 3.81 4 5.24 5.03 1 4.61 3.59 A Organ-count enumeration of viable M. tuberculosis was conducted following 1 month therapy of infected mice.
B Infected but not treated animals which served as the negative (untreated) control.
~ Isoniazid (positive control drug) was dosed at 25 mg/kg orally while the three test drugs were dosed at 100 mg/kg.
The in vivo data for Table 3 was obtained from CD-1 mice infected intravenously with 1 x 107 viable M. tuberculosis (Erdman strain). Twenty-four hours later drug treatment was initiated. All the drugs were given by oral gavage twice daily for four weeks. At the end of therapy, viable cell counts were determined from homogenates of spleens and lungs.
EXAMPLE 1: (~)-N-ff3-f3-tlLOro-4-(4-thiomornholi 'y~yhgavll-2-~~~.-~-Ste 1:' ! ~ - u~m-4-mtr~nhenvl)thiomorp The 3,4-difluoronitrobenzene (2.09 mL, 18.857 mmol) was dissolved in dry CH3CN (50 mL) and then treated dropwise with N,N-diisopropylethyl amine (8.212 mL, 47.143 mmol). The resultant yellow mixture was next treated with thiomorpholine (4.74 mL, 47.143 mmol). The reaction was heated to reflux (85°C) for 16 hours and then it was allowed to cool to ambient temperature over 3 hours, stirring under N2. At this point, the reaction was determined to be complete by TLC (15% EtOAcJhexane, UV short wave). The reaction mixture was first concentrated under reduced pressure and then adsorbed onto silica gel (50 g).
The material was chromatographed on more silica gel ( 175 g, packed with hexane), ~UBS'~ITUTE SHEET RULE 26~
a eluting with 1 L each of 5%, 10% and 15% EtOAc/hexane to give 4.6 g (100%) of the title compound as an orange, crystalline solid with a melting point of 59.5-60.5°C
and a HRMS (M+) calculated for C1~H11N202FS 242.0522, found 242.0525.
Step 2: 4-f2-fluoro-4-(benzvl, oxycarbon, 1)~B,~yllthiomon h~ oL_n_e The 4-(2-fluoro-4-nitrophenyl)thiomorpholine (3.67 g, 8.255 mmol) was dissolved in THF (75 mL) and then treated with a solution of sodium hydrosulfite (26.4 g, 151.56) in water (150 mL). The reaction was slightly exothermic.
After an hour, the reaction was found to be complete by TLC (30% EtOAc/hexane, UV short wave). After cooling to 0 °C in an ice bath, the reaction was quenched with NaHC03 (25.5 g, 303.12 mmol). Next, the reaction was diluted with pH 7 buffer (500 mL). After this solution was saturated with solid NaCI, the product was extracted into CH2C12 (4 x 500 mL). The combined extracts were dried over anhydrous Na2S04, filtered and then concentrated under reduced pressure to yield a yellow solid that was stored in the freezer overnight ( 16 hours). The crude amine ( 1.826 g, .8.601 mmol) was dissolved in dry THF (85 mL) and then cooled to -20 °C
(MeOH/ice bath). The solution was treated with N,N-dimethylaniline ( 1.36 mL, 10.75 mmol) and then allowed to stir at -20 °C for 15 minutes. Next, benzylchloro-formate [1.42 mL (corrected for 95% purity), 9.46 mmol] was added dropwise. A
precipitate formed almost immediately. The reaction was allowed to stir for an additional 15 minutes before the bath was removed. Upon warming to mom temperature under N2 ( 1 hour), the reaction was found to be complete by TLC
(30%
EtOAcJhexane, UV short wave). The reaction was diluted with EtOAc (200 mL) and then washed with both water (2 x 200 mL) and brine (200 mL). The aqueous portions were combined and then back-extracted with more EtOAc (2 x 200 mL).
The organic portions were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to yield a yellowish solid. This crude material was chromatographed on silica gel (150 g, packed with 5% EtOAcJhexane), eluting with 2 L of 5% EtOAc/hexane, 1 L of 10% EtOAc/hexane (CH2C12 was added to maintain solubility) to give 2.65 g (50%) of the title compound as an off white crystalline solid with a melting point of 142°C and a HRMS (M+) calculated for C18H19N202FS 346.1151, found 346.1157.
Step 3: ~,)-f3-f3-fluoro-4-(4-thiomornholinyl)phenvll-2-oxo-5-oxazoLdiyLll methanol The 4-[2-fluoro-4-(benzyloxycarbonyl)aminophenyl]thiomorpholine (2.0 g, 5.77 mmol) was dissolved in dry THF (55 mL) and then cooled to -78 °C (dry ice/acetone bath). This solution was treated with the dropwise addition of n-butyllithium over 6 WO 95/07271 ; PCT/LTS94/08904 minutes. The mixture was stirred at -78 °C for 30 minutes and then treated with (R)-(-)-glycidylbutyrate (0.85 mL, 6.0 mmol) dropwise over 2 minutes. The reaction was stirred at -78 °C for an additional 30 minutes before the ice bath was removed.
The reaction was allowed to warm to ambient temperature, stirnng under N2 overnight (16 hours). At this time, the reaction was determined to be complete by TLC (5% MeOH/CHC13, W short wave). The reaction was diluted with CH2C12 (250 mL) and then washed with both water (3 x 200 mL) and brine (200 mL). The aqueous portions were then back-extracted with more CH2C12 (3 x 150 mL). The organic portions were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to yield a yellow solid. This crude material was chromatographed on silica gel (175 g, packed with 10% CH3CN/CHC13), eluting with a gradient of 1-3% MeOH in 10% CH3CN/CHC13 to give 1.583 g (88%) of the title compound as an ofI=white solid with a melting point of 136-137 °C
and a HRMS
(M+) calculated for C14H17N203FS 312.0944, found 312.0942.
Step 4: (R)-ff3-f3-fluorn-4-(4-thiomorn olir~vl)nhenyll-2-oxo-5-oxazolidinyll The [3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methanol ( 1.465 g, 4.69 mmol) was dissolved in pyridine ( 15 mL) and then cooled to 0 °C (ice bath). This solution was next treated withp-toluenesulfonyl chloride (1.34 g, 7.035 mmol) and allowed to stir at 0°C under N2 for 7 hours. At this point, the reaction was stoppered and stored in the freezer overnight ( 16 hours). In the morning, the reaction showed only a trace of starting material by TLC (5% MeOH/CHC13, tJV
short wave). The product was precipitated by quenching the reaction mixture with ice water ( 100 mL). The solid was isolated by suction filtration and washed thoroughly with water. The title compound, 2.02 g (92%), was recovered as a white solid with a melting point of 141°C and a HRMS (M+) calculated for C21H23N205FS2 466.1032, found 466.1036.
Step 5: (l~,)-ff3-(3-fluoro-4-(4-thiomoroholinvl)nhenyll-2-oxo-5-oxazolidinyll methvllazide The [[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl] p-toluenesulfonate (2.0 g, 4.287 mmol) was dissolved in dry DMF ( 15 mL) and then treated with solid NaN3 ( 1.67 g, 25.722 mmol). The reaction was heated to 65 °C
(external temperature) for 6 hours, after which the reaction was allowed to cool to ambient temperature, stirring over a long weekend (158 hours). At this point, the reaction was found to be complete by TLC (6% CH3CN/CHCl3, UV short wave). The reaction was diluted with EtOAc (300 mL) and then washed with water (3 x 250 mL). The aqueous portions were back-extracted with more EtOAc (2 x 150 mL).
The EtOAc portions were combined, dried over Na2S04, filtered and concentrated under reduced pressure to give 1.447 g (100%) of the title compound as an off white solid with a melting point of 91.5-93 °C and a HRMS (M+) calculated for C14H16N505FS 337.1009, found 337.1009.
Step 6: (S)-N-f f 3-f 3-fluoro-4-(4-thiomoroholinyl) enyll-2-oxo-5-oxazolidinvll methyllacetamide The crude [[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]azide (889 mg, 2.635 mmol) was dissolved in dry THF ( 15 mL) and treated with triphenylphosphine (864 mg, 3.294 mmol). After an hour, the reaction was found to be complete by TLC ( 10% MeOH/CHC13, W short wave). Next, water (0.949 mL, 52.7 mmol) was added and the reaction was heated to 50 °C
for two hours. At this point, the reaction was incomplete; so more water (0.475 mL, 26.35 mmol) was added and the reaction was heated to 60 °C for 5 hours.
The reaction was then allowed to cool to ambient temperature, stirring overnight ( hours) under N2. In the morning, the reaction was found to be complete by TLC
( 10% MeOH/CHCl3, W short wave). The reaction was concentrated and then dried under high vacuum for two hours. Next, the semi-solid was dissolved in CH2Cl2 ( 15 mL) and treated with pyridine (0.320 mL, 3.953 mmol). The reaction was allowed to stir for 15 minutes and then the acetic anhydride (0.497 mL, 5.270 mmol) was added dropwise. After an hour, the reaction was complete by TLC (10% MeOH/CHC13, UV
short wave). The reaction mixture was diluted with CH2C12 (50 mL) and then washed with 1 N HCl (50 mL), saturated NaHC03 (50 mL), and brine (50 mL).
Each aqueous portion was back-extracted with more CH2C12 (2 x 20 mL each). The organic portions were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to yield a white solid. This crude material was chromatographed on silica gel (100 g, packed with 10% CH3CN/CHC13), eluting with 1-2% MeOH in 10% CH3CN/CHC13 to give 667 mg (72%) of the title compound as a white solid with a melting point of 185.5-186.5 °C and a HRMS (M+) calculated for C lgH2pN303FS 353.1209, found 353.1200.
EXAMPLE 2: (S)-N-f f ~-f ~-fluoro-4-( 1.1-dioxothiomoroholin-4-~nhenvll-2-oxo-The N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]
acetamide (280 mg, 0.792 mmol) was slurried in 25% water/acetone solution (12 mL) and then treated with solid 4-methylmorpholine N-oxide (278 mg, 2.376 mmol).
~'~ ~~550 Next, the osmium tetroxide in 2-methyl-2-propanol (0.037 mL of a 2.5%
solution, 15%) was added dropwise. The reaction was allowed to stir for 16 hours under at room temperature. At this time, the reaction was determined to be complete by TLC ( 10% MeOH/CHCl3, LTV short wave). The reaction mixture was quenched with saturated sodium bisulfate ( 15 mL) and then extracted into CH2C12 (4 x 25 mL).
The combined organic layers were then washed with more saturated sodium bisulfite ( 100 mL) and brine ( 100 mL). These aqueous portions were back-extracted with more CHZC12 (2 x 50 mL). All of the organic layers were combined, dried over anhydrous Na2S04, filtered and then concentrated under reduced pressure to yield an off white solid. This solid was adsorbed onto silica gel (2.5 g) and chromatographed on more silica gel (30 g, packed with 10% CH3CN/CHC13), eluting with a gradient of 1-5% MeOH in 10% CH3CN/CHC13 to give 224 mg (73%) of the title compound as a white solid with a melting point of 202-203 °C and a HRMS
(M+) calculated for C16H201V3O5FS 385.1108, found 385.1102.
EXAMPLE 3: SS)-N-ff3-f3-fluoro-4-(1-ozothiomornholin-4-vl)~rhenvll-2-oxo-5-Sodium metaperiodate (42 mg, 0.196 mmol) was dissolved in water ( 1 mL) and then cooled to 0 °C (ice bath). Next, the N-[[3-[3-fluoro-4-(4-thiomorpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (66 mg, 0.187 mmol) was added.
Methanol (3 mL) was added to increase solubility. The reaction was stirred at 0 °C
for an additional 4 hours under N2 before being stoppered and stored in the freezer (65 hours). The reaction was filtered through a medium-porosity sintered glass funnel, rinsing the flask and filter cake with CHCl3 (5 mL). The filtrate was transferred to a separatory funnel, the layers separated, and the water layer further extracted with more CHC13 (3 x 5 mL). The organic layers were combined, dried over anhydrous Na2S04, filtered and then concentrated under reduced pressure to yield 80 mg of a gummy solid. The material was chrnmatographed on silica gel (10 g silica, packed with 10% CH3CN/CHCIg), eluting with a gradient of 1-5%
MeOH
in 10% CH3CN/CHCl3 to give 49 mg (71%) of the title compound as an ofd white solid with a mp of 159-161 °C and a HRMS (M+) calculated for C16H2~N3O4 FS 369.1158, found 369.1182.
EXAMPLE 4: (S1-N-[(3-(3.5-di8uoro-4-(4-morpholinyl)ijphenylj-2-ozo-5-ozazolidinvll methyll-acetamide Step 1: 3.5-difluoro-4-~4-morpholinvl)-nitrobenzene To a solution of 1.468 g of morpholine and 3.0 mL of diisopropylethylamine in 80 mL of acetonitrile was added a soluton of 5.019 g of 2,6-difluoro-4-nitrobenzene (trifluoromethane) sulfonate in 10 mL of acetonitrile. The mixture was heated to reflux for 5 hours, then cooled and concentrated in vacuo. The residue was purified on a silica gel column (3 cm tall, 10 cm diam), eluting with 25% ethyl acetate/hexanes (v/v) and then 2% acetic acid/25% ethyl a~etate/hexanes to give 1.95 g of an orange oil. This was washed with 5% ethyl acetate/hexanes, and the bright yellow solids air dried, mp 91-92 ° C.
Step 2: 3.5-difluoro-4-(4-morpholinyl)-aniline A flask containing a solution of 0.203 g of 3,5-difluoro-4-(4-morpholinyl)-nitrobenzene in 5 mL of ethyl acetate was alternately evacuated and filled with nitrogen three times, then 50 mg of 105 palladium on carbon was added and the fask again evacuated and filled with nitrogen then with hydrogen via a balloon (three times). The mixture was stirred at 20 ° C for a total of 2 hours, then filtered over diatomaceous earth an concentrated in vacuo to give an off white solid, Rf =
0.24 (25% ethyl acetate/hexanes, v/v).
Step 3: N~- ~rbobenzvloxv-3.5-difluoro-4-(4-morpholinyl) aniline To a solution of 0.518 g of 3,5-difluoro-4-(4-morpholinyl)-aniline and 0.432 g of sodium bicarbonate in 20 mL of acetone : water (2:1 v/v) at 0°C was added 0.36 mL of benzyl chlorofonmate over 2 minutes. After 5.5 hours, the mixture was allowed to warm to ambient temperature and after an additional 2.6 hours, the mixture was added to 25 mL
of ethyl acetate and 20 mL of brine. The aqueous layer was extracted with 3 x ZS ml of ethyl acetate and the combined organic layers were dried (MgS04), and concentrated in vacuo to give a solid, mp =
131-133 °C.
Step 4: ~R~N-[[3-[3.5-difluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidin~l]
methanol To a solution of 0.195 g of N-carbobenzyloxy-3,5-difluoro-4-(4-morpholinyl) aniline in 5.0 mL of freshly distilled tetrahydrofiuan at -78°C under nitrogen was added 0.36 mL of 1.6 M n-butyl lithiumlhexane and the mixture stirred for 1.5 hours. At that time 0.10 mL of (R)-glycidyl butyrate was added, and after ~e hour, the flask was removed from the dry ice bath, and allowed to come to ambit temperature. After an additional 2 hours, to the solution was added 2 mL of saturated aqueous ammonium chloride and 5 mL of ethyl acetate, then enough water to make the aqueous layer homogeneous. The separated aqueous layers were extracted with ethyl acetate, then dried (MgS04) and concentrated in vacuo to give a yellow solid. This residue was chromatographed on a 24 cm x 2.5 cm column of silica gel 40-63 ~cm, eluting with a gradient of ethyl acetate/hexane (50%-100%), then with 10-20% methanoUethyl acetate, to give a white solid, mp =123-125 °C.
Step 5: jltl-N f j3~3.5-difluoro-4-(4-morpholinlrl)]phenyl]-2-oxo-5-oxazolidinyl]methanesulfonate To a solution of 0.097 g of (R)-N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methanol and 0.10 mL of triethylamine in 5.0 mI, of methylene chloride at 0 ° C was added 0.030 mL of methanesulfonyl chloride, and after 30 minutes, the flask was removed from the ice bath and allowed to come to ambient temperature. The mixture was concentrated in vacuo, and partitioned between water and ethyl acetate, and the aqueous layer extract with ethyl acetate, and the combined organic layers were dried (MgSO,,) and concentrated in vacuo to give a white solid, Rf = 0. 5 S (ethyl acetate).
Step 6: (Rl-N [(3-j3.5-difluoro-4-(4-morpholinyll)phenYlj-2-oxo-5-oxazolidinyl]
girl]azide To a solution of (R)-N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]
methanesulfonate (0.082 g) in 3.0 mL of dimethylfonmamide was added 0.069 g of sodium azide, and die mixture heated at 60 ° C overnight. The mixture was cooled and concentrated in vacuo, maintaining the apparatus behind a safety shield, to give a white solid. This residue was take up in water and ethyl acetate and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine, then dried (MgS04), and concentrated to give a colorless oil, Rf = 0.29 ( 1:1 v/v ethyl acetate/hexane).
Step 7: ~S~N-[[3 j3.5-difluoro-4-(4-morgholinyll]phen~rl]-2-oxo-5-oxazolidiml]meth~~acetamide The flask containing a solution of 0.632 g of (R)-N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phemrl]-2-oxo-5-oxazolidinyl] methyl]azide in 35 mL of ethyl acetate was evacuated and filled with nitrogen (three times). Then 0.116 g of 10%
palladium/carbon was added and the flask again evacuated and filled with nitrogen (three times), then with hydrogen from a balloon (three times). The mixture was stirred for 3.3 hours, then evacuated and filled with nitrogen (three times), and 3.0 mL of pyridine and 2.0 mL of acetic anhydride were added.
After a period of 40 minutes, the mixture was filtered over diatomaceious earth, and the filtrate concentrated in vacuo overnight. The residue of pink solids was recrystallized from hot ethyl acetate/hexane to give a solid. This was chromatographed on a 2.5 cm x 26 cm 40-63 ~cm silica gel column, eluting with a gradient of 0-10% methanoUethyl acetate (v/v); the combined proper fractions gave a solid which was triturated with ethyl acetate/hexanes (1:1, v/v) to give a white solid, mp =195-198°C.
EXAMPLE 5: (S~~N-Q3-[3-8uoro-4-(4-morpholinyl~jphenyll-2-ozo-5-ozazolidinyl] methy,acetamide Step 1: 3-fluoro-4-(4-mor~holinyll-nitrobenzene To a solution of 19.9 g of morpholine, 28.7 g of 3,4-difluoronitrobenzene, and 14.8 g of diisopropyl ethylamine in 100 mL of ethyl acetate was heated at reflux under nitrogen for 4 h.
The mixture was allowed to cool to room temperature overnight, then 100 mL of ethyl acetate, 150 mL of methylene chloride, and 150 mL of water were added, and the aqueous layer extracted with 2 x 50 mL of methylene chloride and 50 mL of ethyl acetate. The combined organic layers were dried (NazSO,) to give a yellow solid. This was recrystallized from acetone-water to give a yellow solid, mp = 112-113 °C.
Step 2: 3-fluoro-4-(4-mor~holin_yl)-aniline To a suspension of 36.56 g of 3-fluoro-4-(4-morpholinyl)-nitrobenzene and 48.84 g of ammonium formats in 110 mL of tetrahydrofuran and 440 mL of methanol under nitrogen was added 0.524 g of 10% palladium/carbon. After stirring the mixture for a total of 3 hours, the mixture was filtered through diatous earth, and the filter pad was washed with ethyl acetate. The filtrate was concentrated to a volume of about 450 mL and then 200 mL of water was added. This was extracted with 300 mL of ethyl acetate, then the organic layer was washed with 2 x 150 mL of water and then 200 mL of brine, dried (MgS04), and concentrated to give a brown solid, Rf~.47 (1:1 ethyl acetate/hexanes, v/v).
Step 3: N-carbobenzvloxv-3-fluoro-4-(4 morpholinyl) aniline To a solution of 28.91 g of 3-fluoro-4-(4-morpholinyl)-aniline and 27.88 g of sodium bicarbonate in 500 mL of acetone and 250 mL of water at 0°C was added 28.68 g of benzyl chloroformate. After stirring the mixture for 1.5 hours, the mixture was poured onto 1000 cc of ice and water, and the ice allowed to melt. The precipitated solid was collected by filtration and washed with 3 x 250 ml of water, and then dried in a vacuum oven at 75 °C to give a gray-purple solid. This was recrystallized from acetone-water to give a cream-colored solid, mp =123-124°C.
Step 4: (RAN-[[3-[3-fluoro-4-r(4-morpholinyl,)]~yl)-2-oxo-5-oxazolidin~l methanol To a solution of 39.01 g of N-carbobenzyloxy-3-fluoro-4-(4-morpholinyl) aniline in 550 mL of freshly distilled tetrahydrofuran at -78 °C under nitrogen was added 77 mL of 1.6 M n-butyl lithium/hexane via syringe over 30 minutes, and the mixture stirred for an additional 40 minutes. At that time, a solution of 18.32 g of (R)-glycidyl butyrate in 30 mL
of tetrahydrofuran was added over 30 minutes, and after 1.5 hours, the flask was removed from the dry ice bath, and allowed to come to ambient temperature. After stirring the mixture overnight, 20 ml of saturated aqueous ammonium chloride was added, followed by 500 mL of water, and the aqueous layer extracted with ethyl acetate (4 x 300 mL). The combined organic layers were washed with 200 mL of brine and dried (MgS04) to give light purple solid. This is triturated with 1200 mL of l:l ethyl acetate/hexanes (v:v), then recrystallized from ethyl acetate/hexanes to give a white solid, mp =110-113 °C.
Step 5: fR)-N-f [3-[3-fluoro-4-C4-morpholinvl)] eml]-2-oxo-5-oxazolidinvl]
methanesulfonate To a solution of 13.28 g of (R)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinylJ methanol and 8.71 g of triethylamine in 100 mL of methylene chloride at 0°C
under nitrogen was added 7.4 g of methanesulfonyl chloride over 4 minutes. The mixture was allowed to stir at 0°C for 30 minutes, then allowed to warm to ambient temperature. At white solid was a precipitated. Water (175 mL) and 650 mL of methylene chloride and 100 mL of ethyl acetate were added, but the solid did not all dissolve, therefore the mixture was filtered to give a shits solid. Additional material was recovered from the filtrate by multiple extraction of the aqueous layer with methyle~ne chloride. The white solid was dried in a vacuum oven, mp =
183-184 °C.
Step 6: ~Rl-N-[(3 j3-fluoro-4-(4-morcrholinyl)Jpher~rl]-2-oxo-5-oxazolidinyl]
methyl]azide To a solution of (R)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]
methanesulfonate (9.05 g) in 200 mL of dimethylformamide was added 6.367 g of sodium azide, and the mixture heated at 85°C overnight. The mixture was cooled and poured into 500 mL of water and 150 mL of ethyl acetate. The aqueous layer was extracted with 2 x 75 mL of ethyl acetate, and the combined organic layers were dried (MgSO,), and concentrate by vacuum distillati~ to remove the bulk of the dimethylformamide. The brown oil, containing some dimethylformamide, was utilized without further purification, Rf = 0.74 ( 10%
methanoUethyl acetate v/v).
Step 7: (,S')-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyll-2-oxo-5-oxazolidinyl]meth~rltacetamide A flask containing the crude azide (R)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2 21b8560 oxo-5-oxazolidinyl]methyl]azide (assume 24.2 mmol) in 500 mL of ethyl acetate was evacuated and filled with nitrogen (three times). Then 0.602 g of 10%
palladium/
carbon was added and the flask again evacuated and filled with nitrngen (three times), then with hydrogen frnm a balloon (four times). The mixture was stirred for 17 hours, then a fresh balloon of hydrogen was attached. After a period of 5 hours, the flask was evacuated and filled with nitrngen (three times), and 16 mL of pyridine and 10 mL of acetic anhydride were added. After a period of 2.5 hours, the mixture was filtered over diatomaceous earth, washing the pad with ethyl acetate, and the filtrate concentrated in vacuo to give a brown gummy solid. The residue was purified by chrnmatography on a 5.5 cm x 25 cm 40-63 um silica gel column, eluting with a gradient of 2-10% methanol/ethyl acetate (v/v); the combined proper fractions gave an off white solid, which was triturated with ethyl acetate and dried to give an o$' white solid, mp = 181.5-182.5°C.
EXAMPLE 6: (S)-N-f f3-f3-fluoro-4-f 1-f (m-toluenesulfonvDiminol The N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]acetamide (213 mg, 0.603 mmol) was dissolved in dry CH2C12 (11.5 mL) and then treated with hexadecyl-tributylphosphonium bromide ( 138 mg, 0.271 mmol).
To this clear, colorless solution, the chloramine-T ( 165 mg, 0.723 mmol) was added.
The resultant cloudy solution was stirred at room temperature for three hours.
At this time, the reaction was determined to be complete by TLC ( 10% MeOH/CHC13, UV short wave). The reaction mixture was transferred to a separatory funnel and diluted with CH2C12 ( 10 mL). This solution was washed with cold 5% NaOH (20 mL), water (20 mL), and brine (20 mL). The aqueous portions were combined and then back-extracted with more CH2C12 (3 x 20 mL). The organic layers were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The resultant material was chromatographed on silica gel (100 g), eluting with a gradient of 0-6% MeOH in 10% CH3CN/CHCl3 to give 314 mg (99%) of the title compound as a white solid which decomposes at 79°C and has a HRMS
(FAB) calculated for C23H28FN405S2 (M + H)+, 523.1485, found 523.1477.
EXAMPLE 7: (S)-N-ff3-f3-tluoro-4-4-(3-thiazolidinvDl envll-2-oxo-5-Step 1: 3-(2-fluoro-4-nitrophenvl)thiazolidine Using the same general procedure as step 1, of Example 1, 4.092 g (45.90 mmol) thiazolidine was treated with 4.1 mL (37.03 mmol) 3,4-difluornnitrobenzene and 10.0 mL (57.41 mmol) N,N diisopropylethyl amine to provide 2.020 g (24%) of the title compound as an orange solid. Recystallization from methylene chloride /
hexane provided an analytical sample with a melting point of 94 -95 °C.
Step 2: 3-f2-fluoro-4-(benzvloxvcarbonvl)aminonhenvllthiazolidine The 3-(2-fluoro-4-nitrophenyl)thiazolidine ( 1.485 g, 6.513 mmol) was dissolved in tetrahydrofuran (25 mL) and water (5 mL) and then shaken under 40 psi of hydrogen in the presence of Raney nickel (500 mg) for 5 hours. After this time, the mixture was filtered over diatomaceous earth. The filter pad was washed with methanol and the filtrate was concentrated to an aqueous layer. Water (15 mL) and acetone (25 mL) were added to the aqueous mixture and the mixture was cooled in an ice bath. Solid sodium bicarbonate (2.728 g, 32.47 mmol) was added followed by benzyl chloroformate (3.0 mL, 21.01 mmol). The mixture was allowed to warm to room temperature and stirred over 3 nights. Ethyl acetate was added to the mixture and the layers were separated. The aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried (MgS04 ) and concentrated under reduced pressure to provide 3.925 g crude material as a dark oil. The crude was chromatographed on a silica gel column (27 cm x 4.5 cm, 40 - 63 u), eluting with 500 mL 40% hexane/methylene chloride, 1L 20% hexane/methylene chloride, 500 mL
10% hexane/methylene chloride, 500 mL methylene chloride and 500 mL 3%
methanol/methylene chloride to provide 480 mg of the title compound as yellow solids and 950 mg of the title compound contaminated with benzyl alcohol. In order to remove the benzyl alcohol contaminate, the contaminated material was treated with triethyl amine (0.6 mL, 4.31 mmol), butyric anhydride (0.45 mL, 2.86 mmol) and a small amount of 4-dimethylamino pyridine at 0°C. After 35 minutes the mixture was concentrated and chromatographed on a silica gel column (23.5 cm x 2.5 cm, 40 - 63 u), eluting with 250 mL 10% ethyl acetate/hexane and 500 mL
15%
ethyl acetate/hexane to provide 700 mg of the title compound as light yellow solids.
In all, 1.180 g (59%) of the title compound was obtained. Recrystallization frnm ethyl ether/hexane provided an analytical sample with a melting point of 90 -92°C.
Step 3: (R)-f 3-f 3-fluoro-4-(3-thiazolidinyl)phenvll-2-oxo-5-oxazolidinyll methanol Using the same general procedure as step 3 of example 1, 3-[2-fluoro-4-(benzyloxycarbonyl) aminophenyl]thiazolidine (692 mg, 2.24 mmol) was treated sequentially with n-butyllitium ( 1.5 mL, 2.40 mmol) and (R)-(-)-glycidylbutyrate (0.33 mL, 2.33 mmol) to provide 500 mg (78%) of the title compound.
Recystallization from methylene chloride/hexane provided an analytical sample with w --CA 02168560 2001-05-02 4717.P CP
a melting point of 96 - 97°C.
Step 4: (R) ff3 f3 fluoro 4 (3 thiazolidinyl)phen3~~2-oxo-5-ozazolidiny~llmethvll-(R)-[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl] methanol (300 mg, 1.05 mmol) and triethylamine (0.30 mL, 2.16 mmol) in 15 mL of methylene chloride was cooled in an ice bath and treated with methanesulfonyl chloride (0.10 mL, 1.29 mmol). The mixture was removed from the ice bath and stirred at room temperature for 45 minutes then 10 mL of 1 ~T HCl was added. The resulting layers were separated and the aqueous layer was extracted with methylene chloride.
The combined organic layers were washed with saturated aqueous sodium bicarbonate, dried (MgS04), and concentrated under reduced pressure to provide 342 mg (87%) of the title compound as a yellow solid, Rf--0.58 (ethyl acetate).
Step 5: ~S)-N-ff3-f3-fluorn-4-(3-thiazolidiny11R~1.~1y11-2-oxo-5-oxazoLdinvll The (R)-[[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-ozazolidinyl]methyl]-methanesulfonate (342 mg, 0.910 mmol) was slurried in 5 ml of tetrahydrofuran isopropanol ( 1:1) and treated with 5.0 mL of concentrated ammonium hydroxide in a sealed tube at 85 - 95°C for 6 hours. The mixture was then poured into 20 mL
water and 20 mL methylene chloride. The layers were separated and the aqueous layer was extracted with methylene chloride (3x). The combined organic layers were washed with brine, dried (MgS04) and concentrated under reduced pressure to a yellow oil. The crude was taken up in 20 mL methylene chloride and cooled in an ice bath. The mixture was treated with 0.5 mL pyridine and 0.5 mL acetic anhydride and removed from the ice bath. After stirring of 30 minutes at room temperature, the mixture was concentrated under reduced pressure to an oil.
The crude was chromatographed on a silica: gel column (23 cm x 2.5 cm, 40 - 63 p), eluting with 200 mL 75% ethyl acetate/hexane, 250 mL ethyl acetate and 500 mL
10% methanoUethyl acetate to provide 190 mg of the title compound as a yellow solid (53% yield from (R)-[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]
methanol). Crystallization of the yellow solid from methylene chloride/hexane provided 113 mg of the title compound as a light yellow solid with a melting point of 103 - 105°C.
Step 6: ~S~-N-[(3~3-fluoro-4,~4-morpholinvlllohemrl]-2-oxo-5-oxazc>lidinvllmethvll-h imide 'Ihe methanesulfonate (of Ex. 5, step 5), (32.559 g, 87.0 mmol of compound from Step 5, above) and potassium phthalimide (32.348 g, 174.6 mmol) were weighed wCA 02168560 2001-05-02 4717.P CP
into a flask. Acetonitrile (500 ml) was added, and the mixture was refluxed under nitrogen atmosphere for 2 days, and was stirred at room temperature over the weekend. The reaction mixture, which contained a white precipitate, was filtered.
The solid was carefully washed with acetonitrile. The filtrate was then evaporated to give the desired product, as a yellow solid (22.$07 g). Because of the poor recovery, the white solid was stirred with 600 ml of acetonitrile overnight.
It was then filtered. The solid was again carefully washed with more acetonitrile.
The solvent was evaporated to give the desired compound, (7.964 g). This extraction process was repeated and an additional 4.408 g of product was obtained (35.179 g total). The crude material was recrystallized from acetone and water in several batches ( 13.138 g, boiling, 800 ml acetone, 900 ml water, cooled to room temperature) to give 31.745 g (86%) of the product, as white crystals in "first crops"
along with 2.004 g (5%) in "second crops".
Melting Point: 199-200 °C.
Mass Spectrum: m/e (rel. abundance): 425 (100, M+), 426 (25.6), 186 (23.9), (14.5), 175 (16.4), 160 (27.1), 150 (18.9), 149 (16.1), 148 (11.5), 77 (11.4);
exact mass calc'd for C22H20FN305~ 425.137. Found: 425.1387.
Analysis calc'd for C22H20FN305~ C, 62.11; H, 4.74; N, 9.88. Found: C, 62.06;
H, 4.78; N, 9.88.
Specific Rotation: [a]D -57° (c 0.834, CHC13).
Step 7: (Sl N ff3 [3 fluoro-4 4 morehol' )loheny~l-2-oxo-5-oxazolidinvllmethyllamine Ethanol (320 ml) and aqueous methylamine (30 ml of 40%, 386.3 mmol) were added to a flask containing the phthalimido oxazolidinone, from Step 6, (27.013 g, 63.5 mmol). The suspension which was placed under nitrogen atmosphere, was heated at 70 °C for 3 hr, and refluxed for 1 hr. A 55 ml aliquot was removed for purification (the remainder was converted to the acetamide U-100766). This was purified in two batches, on a medium pressure silica column (40 x 63 u, 4.2 cm x 28 cm, packed with 3% methanol/methylene chloride, eluted with 500 ml 3%, 2000 ml 5%, 1000 ml 10% methanol/methylene chloride, collected 50 ml fractions) to give 3.681 g of the amine, the title compound, as a white solid.
mp 103-104 °C.
Mass Spectrum: m/e (rel. abundance): 295 (100, M+), 237 (8.9), 222 (10.5), 209 (29.4), 164 (28.6), 151 (53.9), 150 (20.5).
Analysis calc'd for C14Hi8FN303: C, 56.94; H, 6.14; N, 14.23. Found: C, 56.56;
H, 6.24; N, 14.05.
.. . _.. __ _.. _... .... .__ _--_ ...... CA 02168560 2001-05-02 4717.P CP
Step 8: jS'~[(3-[3-fluoro-4-~4-morpholin3rl)]phernrlj-2-oxo-5-oxazolidin~rl]methyl]-benz5rloxyacetamide A solution of the aminomethyl oxazolidinone, from Step ?, (0.201 g, 0.68 mmol) in 5 ml of pyridine was cooled to 0 °C under nitrogen atmosphere.
Then benzylosyacetyl chloride (0.13 ml, 0.82 mmol) was added uia syringe. The reaction mixture was stirred for 24 hr as it gradually warmed to ambient temperature.
The solvent was then evaporated and the residue was purified on a medium pressure silica column (43 x 60 u, 2.4 cm x 26 cm, packed with 5% methanoUmethylene chloride, eluted with 5% and 10% methanoUmethylene chloride, 15 ml fractions were collected) to give 0.296 g (98%) of the improved quality material as a white solid. A
portion of this solid (0.053 g) was recrystallized from methylene chloride and hexanes to give 0.036 g of the desired material as white crystals, mp 104.5-106 °C.
Mass Spectrum: m/e (rel. abundance): 443 (100, M+), 399 (14.2), 234 (28.3), (16.8), 196 (10.1), 176 (9.3), 164 (13.2), 150 (10.6), 91 (60.2).
Analysis calc'd for C23H26FN305~ C. 62.29; H, 5.91; N, 9.47. Found: C, 62.04;
H, 5.93; N, 9.37.
EXAMPLE 8: ~~'~-N [[3-13-fluoro-4-(4-mo~avlllnhen~l-2-ozo-5-ozazolidinvll-methvllhvdrozvacetamide The benzyloxyacetamidomethyl oxazolidinone, product of Step 8 from Example 7, (0.163 g, 0.37 mmol) was dissolved in ethyl acetate ( 10 ml) and methanol (1 ml) and was placed under nitrogen atmosphere by alternately evacuating and fi11~ the system with nitrogen 3x. Then 10% palladium on carbon (0.050 g) was added and the system was again evacuated and filled with nitrogen 3x. Hydrogen was then introduced into the system 2x uia a hydrogen balloon. The reaction mixture was stirred over a weekend. The reaction mixture was then filtered through diatomaceous earth which was carefully washed with 5% methanol/ethyl acetate. The solvents were evaporated to~give 0.120 g of crude material which vas purified on a medium pressure silica column (43 x 60 u, 1.6 cm x 27 cm, packed and eluted with 10% methanol/methylene chloride, collected 10 ml fractions) to give 0.026 g (20%) of the desired product as a white solid, mp 114-115 °C.
Mass Spectrum: m/e (rel. abundance): 353 (100, M+), 309 (20.7), 234 (28.4), (7.6), 209 (21.8), 196 ( 10.2), 176 (24.9), 164 ( 17.4), 151 ( 14.9), 138 ( 19.0), 101 ( 12.5), 56 ( 16.8), 43 ( 18.0).
TLC: 10% Methanol/Methylene Chloride: Rf = 0.39.
4717.P CP -26-EXAMPLE 9: fS'~(j3-j3-tluoro-4-(4-morpholinYl)jphenyl]-2-oao-5-oaazolidinvll-methyl]formamide Acetic anhydride (0.35 ml, 3.7 mmol) was added to a formic acid (2 ml, 53 mmol) solution of the aminomethyl oxazolidinone, product of Step 7 from Example 7, (0.199 g, 0.67 mmol). This solution was stirred under nitrogen atmosphere for two weeks. Then, although there was still evidence of starting material by TLC, the reaction mixture was evaporated. The residue was purified on a medium pressure silica column (43 x 60 u, 2.4 cm x 25 cm, packed and eluted with 5%
methanol/methylene chloride, 15 ml fractions were collected) to give 0.162 g (74%) of the desired material as a white foamy solid, mp 44-47 °C.
Mass Spectrum: m/e (rel. abundance): 323 ( 100, M+), 279 (5.9), 265 (6.7), 234 (11.1), 221 (6.5), 209 (6.8), 176 (13.2), 164 (8.3), 151 (13.0), 138 (8.6).
EXAMPLE 10: (S'~N-((3-(3-fluoro-4-(4-morpholin~rl)]phenyl]-2-oao-5-oaazolidi~ll-methyl]methvlcarbamate A methylene chloride solution (2 ml) of the aminomethyl oxazolidinone, product of Step 7 from Example 7, (0.209 g, 0.71 mmol) was cooled to 0 °C under nitrogen atmosphere. Triethylamine (0.12 ml, 0.86 mmol) and methyl chloroformate (0.25 ml, 3.23 mmol) were added. The reaction mixture gradually warmed to ambient temperature. After stirring 4.5 hr, the solvent was evaporated to give a foamy pink solid. This residue was purified on a medium pressure silica column (43 x 60 u, 2.4 cm x 25 cm, packed and eluted with 5% methanol/methylene chloride, collected 15 ml fractions) to give 0.188 g of the desired product as a white solid. The upgraded product was then recrystallized from methylene chloride and hexanes to give 0.168 g (67%) of white crystals, mp 147.5-148.5 °C. Another 0.018 g (7%) of the desired compound was isolated in a subsequent recrystallization.
Mass Spectrum: m/e (rel. abundance): 353 ( 100, M+), 295 (4.3), 234 ( 14.6), (6.7), 209 (6.7), 176 (16.6), 164 (14.0), 150 (10.6), 138 (13.7), 114 (4.8), 88 (6.1), 43 ( 10.9).
Specific Rotation: [a]D -14° (c 0.844, CHCl3).
4717.P CP -27-EXAMPLE 11: (S)-N-(f3-13-fluoro-4-l4-mo holin~I~lghenvl~-2-oao-5-oaazolidinvll meth~rl]dichloroacetamide A methylene chloride solution (2 ml) of the aminomethyl oxazolidinone, product of Step 7 from Example 7, (0.200 g, 0.68 mmol) was cooled to 0 °C under nitrogen atmosphere. Then triethylamine (0.11 ml, 0.79 mmol) was added.
Dichloroacetyl chloride (0.11 ml, 1.14 mmol) was then added slowly vizz syringe over 3 min, some gas evolved. The reaction mixture slowly came to ambient temperature as it stirred overnight. The solvent was evaporated and the residue was purified on a medium pressure silica column (43 x 60 p, 2.5 cm x 27 cm, packed and eluted with 2% methanol/methylene chloride, collected 15 ml fractions) to give 0.140 g (51%) of the desired material as a light tan solid, mp 193-196 °C.
Mass Spectrum: m/e (rel. abundance): 407 (M+2+, 64.9), 405 (M+, 100), 176 ( 12.3), 164 (18.1), 151 (26.7), 150 (18.7), 149 (17.8), 138 (19.6).
Analysis calc'd for C 16H 18C12FN304: C, 47.31; H, 4.4?; N, 10.34. Found: C, 47.12; H, 4.67; N, 10.20.
Specific Rotation: [a]D -36° (c 0.955, CHC13).
R' Rz R~ Rz X~ H ~ Y ~ ~ NOz X' N ~ ~ NOz ~CHz~ n Rz - ~CHz ~ n Rz R/ \ R: R~ Rz O
X N ~ ~ NHz X' N ~ ~ "OR, ~CHz ~ n Rz - ~--~CFIz ~ x -n R
R~ Rz ~ O R' Rz O
X/ N . ~ ~ N ~0 X~ ~ \ N ~0 .
~CHz~n Rz- ....H ~--~CHz~n z- ..,.H
OH R ORS
R~ Rz O R~ Rz 0 X N ~ ~ N- 'O X N ~ ~ N- 'O
~--~CHH ~n .'..H CH n "H O
z Rz- ~Rt z Rz- ~ _C_R
Rx O Rx 0 O= ~ ~ ~ N"O ~ ~ ~ ~ N~O
~CHx,~ R - ..,.H O O ~--~CHx~~ R - ...,H O
x II x II
-C-R ~-C-R
o Rx o S~ N ~ ~ N~O ~ ~ ~ ~ N~0 '--~CHx~n Rx- "..H O ~N ~CHx~n Rx- ~ 0 p-C-R d p-C-R
Rx 0 ~N= ~ ~ ~ N"O
RIo ~CHx~ ".~H O
n -C-R
)background of the Invention The subject invention discloses oxazine and thiazine oxazolidinone derivatives. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, mycobacterium avium and Mycobacterium spp..
Information Disclosure The present compounds are similar to piperazine containing ring structures such as those disclosed in the publications below except that the distal nitrogen atom is replaced with an oxygen, sulfur, sulfinyl, sulfonyl, sulfimidoyl or sulfonimidoyl. The instant compounds are unique in that typically the unsubstituted piperazinyl oxazolidinone compounds have little useful antibacterial activity whereas the activity observed for the corresponding oxazine and thiazine derived oxazolidinones is high.
Publication W093/23384 discloses oxazolidinones containing a substituted diazine moiety and their uses as antimicrobials.
Publication W093/09103 discloses substituted aryl and heteroaryl-phenyl-oxazolidinones useful as antibacterial agents.
Publication W090/02744 discloses 5'indolinyl-S~i-amidomethyloxazolidinones, 3-(fused-ring substituted)phenyl-5(3-amidomethyloxazolidinones, and 3-(nitrogen substituted)phenyl-5(3-amidomethyloxazzolidinones which are useful as antibacterial agents.
Other references disclosing various oxazolidinones include U.S. Patent 4,801,600, 4,921,869, Gregory W.A., et al., J. Med. Chem., 32, 1673-81 (1989); Gregory W.A., et al. ,j~
Med. Chem., 33, 2569-78 (190); Wang C., et al., Tetrahedron, 45, 1323-26 (1989); and Brittelli, et al., J. Med. Chem., 35, 1156 (1992).
European Patent Publication 352,781 discloses phenyl and pyridyl substituted phenyl oxazolidinones.
European Patent Publication 316,594 discloses 3-substituted styryl oxazolidinones.
3 0 European Patent Publication 312,000 discloses phenylmethyl and pyridinylmethyl substituted phenyl oxazolidinones.
WO 95/07271 ~ ' PCT/LTS94/08904 Summary of the Invention In one aspect the subject invention is a compound of structural Formula I:
R
O
~ o X N N O H II
~N-C-R
~ 2 ) L~V/n or pharmaceutically acceptable salts thereof wherein:
X is O, S, SO, SO2, SNRl~ or S(O)NR10;
R is (a) hydrogen, (b) C1-C8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C1-C8 alkoxy, C1-C8 acyloxy or O-CH2-Ph, (c) C3-Cs cycloalkyl, (d) amino, (e) C1-C8 alkylamino, (f) C1-C8 dialkylamino, or (g) C1-Cg alkoxy;
Rl is H, except when X is O then Rl can be H, CH3, CN, C02H, C02R or (CH2)mRll (m is 1 or 2);
R2 is independently H, F or Cl;
R3 is H except when X is O and Rl is CH3 then R3 can be H or CH3;
Rl~ is independently H, C1-C4 alkyl (optionally substituted with chloro, fluoro, hydroxy, C1-C8 alkoxy, amino, C1-C8 alkylamino or C1-C8 dialkylamino) or p toluenesulfonyl;
Rll is hydrogen, OH, OR, OCOR, NH2, NHCOR or N(R1~)2; and nis0, lor2.
Preferred compounds where n is 0 are:
(a) (S)-N-[[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4-( 1-oxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]acetamide; or (d) (S~ N-[[3-[3-fluoro-4-(3-oxazolidinyl)JphenylJ-2-oxo-5-oxamlidinylJ
methyl] acetamide.
Preferred compounds where n is 1 are:
(a) (,S~ N-[[3-[3-fluoro-4-(4~hiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methylJ-acetamide;
(b) (S~ N-[[3-[3-fluoro-4-(1,1-dioxothiomorpholin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide;
(c) (S~ N-[[3-[3-fluoro-4-(1-oxothiomorpholin-4-yl)phenylJ-2-oxo-5-oxazolidinyl)methylJ-aceetamide; _ (d) (S') N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phenyl)-2~xo-S~xazolidinyl)methylJ-acetamide;
(e) (,S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2~xo-5-oxazolidinyl]methyl]acetamide;
(f) (S~ N-[[3-[3-fluoro-4-[1-[(p-toluenesulfonyl)imino)thiomorpholin-4-yl]phenyl)-2-oxo-5 oxazolidinyl]methyl]acetami~;
(g) (S') N-[[3-[3-fluoro-4-(4-morpholinyl)JphenylJ-2-oxo-5-oxazolidinyl]methyl]-hydroxyacetamide;
(h) (S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]-formamide;
(i) (S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl)-2-oxo-5-oxaTOlidinyl]methyl]methyl-carbamate; or (j) (S~ N-[[3-[3-fluoro-4-(4-morpholinyl)]phenylJ-2-oxo-5-oxazolidinyl]methyl)-dichloroacetamide;
Preferred com~2ound~ where n is 2 are:
(a) (S~-N-[[3-[3-fluoro-4~he~Cahydrothiazepin-4-yl)phenyl)-2-oxo-5-oxazolidinyl]methyl]-acetamide;
(b) (S~ N-[[3-[3-fluoro-4-(1,1-dioxohexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinylJmethyl]acetamide;
(c) (S~ N-[[3-[3-fluoro-4-(1-oxohexahydrooxazepin-4-yl)]pl~nyl]-2-oxo-5-oxawlidinyl]methyl]acetamide; or (d) (,S~ N-[[3-[3-fluoro-4-(hexahydrothiazepin-4-yl)phenyl]-2~xo-5-oxazolidinyl)methyl]-acetamide.
In another aspect, the subject invention is directed toward a method for treating microbial infections in patients by administering to a patient in need thereof an effective amount of a compound of Formula I as described above. The compound can be administered in a pharmaceutical composition either orally, parenterally or topically. Preferably, the compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weightJday, more preferably, from about 3.0 to about 50 mg/kg of body weightJday.
Detailed Description of the Invention The present invention discloses oxazine and thiazine oxazolidinones of structural Formula I as defined above. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, particularly gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacteroides spp. and Clostridia spp. species, and acid-fast organisms such as Mycobacterium tuberculosis, Mycobacterium dvium and Mycobacterium spp..
The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Ci-C~ defines the number of carbon atoms present from the integer "i" to the integer "j" inclusive. Thus, C1-C3 alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl; C1-C8 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomeric forms thereof.
The term C1-C8 alkylamino means an amino moiety (-NH-) containing one alkyl moiety having 1 to 8 carbon atoms. The term C1-C8 dialkylamino means an amino moiety containing two alkyl moieties having 1 to 8 carbon atoms, for example, propylamino and dipropylamino respectively. The C1-C8 alkyl or C1-C4 alkyl groups can be optionally substituted with chloro, fluoro, hydroxy, C1-C8 alkoxy, amino, C1-C8 alkylamino, C1-C8 dialkylamino or -O-CHZPh where "Ph" is phenyl. "Acyloxy"
are groups such as methylcarbamate, ethylcarbamate,etc. Such optionally substituted C1-C8 alkyl grnups can include 1-chloropropyl, 1-fluoropropyl 3-chloropropyl, 3-fluoro propyl, 1-hydroxy butyl, 2-hydroxy butyl, 1-methoxypropyl, 1-octyloxy propyl, 1-amino propyl, 1-aminooctyl, 1-butylaminopropyl, 1-dibutylamino-propyl and the like.
Pharmaceutically acceptable salts means acid addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, prnpionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like when a basic group is present. These salts may be in hydrated form.
The benzene ring, in addition to being unsubstituted, can be substituted with one or more halogen atoms in the series fluorine or chlorine. Thus, the R2 groups can be independently either hydrogen atoms or halogen atoms in a variety of substitution patterns.
The RZ substituents are preferably both fluorine and, more preferably, fluorine and H.
The preferred absolute configuration at C-5 of the oxazolidinone ring of compounds claimed in this invention is as represented in the structure of Formula I.
This absolute configuration is called (S) under the Cahn-Ingold-Prelog nomenclature system. It is this (S)-enantiomer which is antibacterially active. The racemic mixture is useful in the same way and for the same purpose as the pure (S)-enantiomer; the difference is that twice as much racemic material must be used to produce the same antibacterial effect. It will be apparent to one skilled in the art that appropriate modifications to the morpholine or thiomorpholine ring systems of compounds of Formula I, for example the incorporation of a second chiral center (Rl not H), will lead to diastereomers. These diastereomers, in racemic and enantiomerically enriched fortes, are also within the scope of the compounds of Formula I of the invention.
Optically pure material could be obtained either by resolution from a racemic mixture by selective crystallization of a diastereomeric salt from, for example, an intermediate amine with an appropriate optically active acid such as dibenzoyl tartrate or 10-camphorsulfonic acid, followed by treatment with base to afford the optically pure amine.
The preferred method of preparation of oxazolidinones of Formula I in enantiomerically pure form is depicted in Charts 1 and 2.
As shown in Chart 1, oxazines and thiazines such as thiazolidine (R1= H, X = S, n = 0), oxazolidine (Rl = H, X = O, n = 0), morpholine (Rl = H, X = O, n = 1), thiomorpholine (Rl = H, X = S, n = 1), a substituted morpholine (Rl not H, X =
O, n = 1), hexahydro-1,4-thiazepine (Rl = H, X = S, n = 2), hexahydro-1,4-oxazepine (R1= H, X = O, n = 2), or a substituted hexahydro-1,4-oxazepine (R1 not H, X =
O, n = 2) of structure 1 are reacted with a functionalized nitrobenzene 2 (Y =
halogen or trifluoromethanesulfonate) in the presence of a suitable base such as N,N
diiso-propylethylamine and in a suitable solvent such as acetonitrile, tetrahydrofuran (THF) or ethyl acetate at reflux temperature to provide the adducts 3. When necessary, the Rl sidechain of 1 is protected with a suitable protecting groups) such as a benzyl or other variants as described in Greene, T. W.; Wuts, P. G. M.
"Protective Groups in Organic Synthesis", 2nd ed.; John Wiley & Sons: New York ( 1991) which is removed later in the synthesis. When X = O, the nitrn group of 3 is WO 95/07271 ~ PCT/L1S94/08904 then reduced by hydrogenation in the presence of a suitable catalyst such as palladium on carbon (hydrngen supplied in the form of a gas or indirectly via ammonium formate) in a suitable solvent such as ethyl acetate, tetrahydrofuran, methanol and mixtures thereof. Alternatively, and preferably in the case where X = S, the vitro grnup of 3 can be reduced by the action of aqueous sodium hydrosulfite in tetrahydrofuran at ambient temperature to give the anilines 4.
The anilines 4 are then converted to their benzyl (R4 = CH2Ph) or methyl (R4 =
CH3) urethane derivatives b, employing standard Schotten-Baumann conditions or other variations known to one skilled in the art. The urethanes b are then deprotonated with a suitable base such as n-butyllithium or LiN(SiMe3 )2 in a suitable solvent such as tetrahydrofuran ("THF") and at a suitable temperature such as -78 to -40°C
to give a lithiated intermediate which is then treated with commercially available (-)-(R)-glycidyl butyrate. Warming to ambient temperature then directly affords the hydroxymethyl-substituted oxazolidinones 6 in enantiomerically enriched form.
Compound 6 is then converted to the corresponding mesylate 7 (R5 = methane-sulfonyl) or aryl sulfonate 7 (R5 = ArS02, for example p-toluenesulfonyl) by the action of, for example, methanesulfonyl chloride/pyridine or methanesulfonyl chloride/triethylamine/dichloromethane or p-toluenesulfonyl chloride/pyridine.
The resultant sulfonate derivative 7 is then reacted with an azide source such as sodium or potassium azide in an aprotic solvent such as N,N dimethylformamide (DMF) or 1-methyl-2-pyrrolidinone optionally in the presence of a catalyst such as 18-crown-6 at a temperature of 50-90 °C to afford the azide 8 (Rs = N3). The azide is then reduced by hydrogenation with palladium on carbon or a platinum catalyst in an appropriate solvent such as ethyl acetate or methanol to give the corresponding amine 8 (R6 = NH2). Alternatively, the azide can be reduced by treatment with a trivalent phosphorus compound such as triphenylphosphine in a suitable solvent such as tetrahydrofuran followed by the addition of water. Alternatively, the mesylate or aryl sulfonate can be displaced with potassium phthalimide in acetonitrile at reflux or other suitable solvent. The phthalimide 8 (Rs = phthalimide) is then deprotected by the addition of aqueous methyl amine in refluxing ethanol, to give the amine 8 (Rs = NH2). Alternatively, the amine 8 may be obtained directly frnm mesylate 7 by treatment with ammonium hydrnxide by refluxing in isopropanol or THF. The amine 8 is then acylated by reactions known to those skilled in the art to give oxazolidinones of structure 9. For example, the amine can be reacted with an acid chloride or anhydride in a basic solvent such as pyridine at a temperature ranging frnm -30 to 30 °C to prnvide the acylated compound 9 (R = optionally substituted alkyl). It will be apparent to one skilled in the art that other aryl groups within the scope of this invention can be readily appended to the amine 8 (Rs = NH2) by standard acylation techniques, for example, those highlighted in March, J. "Advanced Organic Chemistry", 3rd ed.; John Wiley &
Sons: New York, 1985; p 370-375, to give additional examples of 9. At this juncture, any appended protecting group on the Rl sidechain of the branched morpholine or hexahydrn-1,4-oxazepine congeners (X = G is removed, where applicable, employing appropriate conditions such as those noted in Greene, T. W.; Wuts, P. G. M., "Protective Groups in Organic Synthesis," 2nd ed.; John Wiley & Sons: New York (1991). The compounds of structure 9 represent examples of oxazine- and thiazine-substituted oxazolidinone antibacterial agents of Formula I, which are the subject of this invention.
As shown in Chart 2, the thiazolidine-containing or thiomorpholine-containing oxazolidinones 10 (and also the hexahydro-1,4-thiazepine-containing variants), themselves examples of antibacterial agents of Formula I, can be further elaborated to additional compounds of Formula I as shown in Chart 2.
Specifically, 10 can be oxidized to the corresponding sulfoxides 11 (X = sulfinyl) with sodium metaperiodate in a mixture of water and methanol. In addition, compounds 10 or 11 can be oxidized to the sulfones 12 (X = sulfonyl) by treatment with oxone or 4-methylmorpholine N-oxide and catalytic osmium tetroxide in aqueous acetone.
Sulfides 10 can also be converted to sulfilimines 13 (X = sulfimidoyl). For example, treatment of 10 with chloramine-T trihydrate in dichloromethane in the presence of a suitable phase transfer catalyst such as hexadecyltributyl- phosphonium bromide affords compounds 13 (Rl~ = p-toluenesulfonyl). Additional sulfilimines can be prepared by methods known to one skilled in the art, for example, those disclosed in Oae, S.; Furukawa, N. "Sulfilimines and Related Derivatives"; American Chemical Society: Washington, D.C., 1983. Sulfoximine derivatives 14 (X =
sulfonimidoyl) are also accessible by further elaboration of the sulfoxides 11 and sulfilimines 13.
Numerous methods and variations for these transformations are available: ( 1) Johnson, C. R., "Comprehensive Organic Chemistry"; Jones, N., ed.; Pergamon Press: Oxford, 1979; Vol. 3, Chapter 11.11, (2) Johnson, C. R., Aldrichimica Actd, 1985, 18, 3-4 and references cited therein, (3) Johnson, C. R.; Lavergne, O., J. Org.
Chem. 1989, 54, 986-988 and references cited therein, (4) Johnson, C. R.;
Rigau, J.
J., J. Org. Chem. 1968, 33, 4340-4343, and (5) Oae, S.; Furukawa, N., "Sulf'ilimines and Related Derivatives"; American Chemical Society: Washington, D.C., 1983;
p 297-317 and references cited therein. For example, oxidation of N-WO 95107271 ~ PCT/US94108904 _g_ tosylsulfilimines 13 (Rl~ = p-toluenesulfonyl) with aqueous sodium hypochlorite in a mixture of ethyl acetate and dichloromethane in the presence of tetrabutyl-ammonium bromide affords N tosylsulfoximines 14 (Rl~ = p-toluenesulfonyl). The tosyl group of 14 may be removed under acidic conditions, for example, with concentrated sulfuric acid, to give 14 (R1~ = H). Further alkylation, acylation, or sulfonylation of the sulfoximine nitrogen under selected conditions described in the above references then prnvides additional examples of the sulfoximines 14 which are also antibacterial agents of Formula I claimed in this invention.
Representative prncedures for converting the sulfoxides 11 into the sulfoximines 14 can be found in the references listed immediately above. For example, 11 can be reacted with O-(mesitylsulfonylhydroxylamine) in a suitable solvent such as dichloromethane, as described in Johnson, C. R. et al., J. Org. Chem. 1974, 39, 2458-2459, to furnish the corresponding sulfoximines 14 (R1~ = H). Functionalization of the sulfoximine nitrogen as described above affords additional examples of 14. Alternatively, 11 can be reacted with p-toluenesulfonyl azide in the presence of a suitable promoter such as R,aney copper and in a suitable solvent such as methanol or methanol/dichloro-methane, as described in Johnson, C. R. et dl., J. Am. Chem Soc. 1973, 95, 4291, to provide the N tosylsulfoximines 14 (R1~ = p-toluenesulfonyl). As described above, the tosyl group may be removed and replaced with alternative groups to give additional examples of sulfoximines 14.
It will be apparent to those skilled in the art that the described synthetic procedures are merely representative in nature and that alternative conditions are known, for example, substituted morpholines where Rl is not equal to hydrogen:
Araki, K. et al. , poster presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 23-26, 1988, Los Angeles, CA, Abstract No. 947; and JP 03,291,274, JP 03,148,276, JP 03,066,688, JP
03,048,682, JP 02,019,380, JP 02,115,182, and EP 311,948. Synthesis of substituted hexahydro-1,4-oxazepine where Rl is not equal to hydrogen can be followed from Araki, K.
et al. , JP 02,115,181. For n is 0, see, Oh, Chang-Hyun et al., J.Antibiotics, 47:126-28 ( 1994).
These compounds are useful for treatment of microbial infections in humans and other warm blooded animals such as cattle by either parenteral, oral, or topical administration. An example, where the subject invention would be useful in cattle is in the treatment of mastitis.
The pharmaceutical compositions of this invention may be prepared by combining the compounds of Formula I of this invention with a solid or liquid _g_ pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent.
Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or apprnpriate amounts of the active component, that is, the compound of Formula I according to this invention.
The quantity of active component, that is the compound of Formula I
according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound, the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
In therapeutic use for treating, or combatting bacterial infections in patients such as humans and other animals that can be diagnosed with bacterial infections, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about 0.1 to about 100 mg/kg, more preferably about 3.0 to about 50 mg/kg of body weightJday.
It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
The compounds of Formula I according to this invention are administered parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound according to Formula I as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to prnvide a suitably buffered isotonic solution, for example, having a pH of about 3.5-7. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents.
The compound according to Formula I generally will be dissolved in the carrier in an amount.sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage. The compounds of Formula I
according to this invention are advantageously administered orally in solid and liquid dosage forms.
As a topical treatment an effective amount of Formula I is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Preparation of such creams and gels is well known in the art and can include penetration enhancers.
Antimicrobial activity was tested in vivo using the Murine Assay procedure.
Groups of female mice (six mice of 18-20 grams each) were injected intraperitoneally with Staphylococcus dureus bacteria which were thawed just prior to use and suspended in brain heart infusion with 4% brewers yeast (Staphylococcus aureus) or brain heart infusion (Streptococcus species). Antibiotic treatment at six dose levels per drug was administered one hour and five hours after infection by either oral intubation or subcutaneous routes. Survival was observed daily for six days.
values based on mortality ratios were calculated using probit analysis. The subject compounds were compared against vancomycin as a control. The data are shown in Table 1.
Table 1 In Vivo Activity of Examples 1-5 Against S. aureus UC~ No. 9213 ED (mg/kg) Example No.
Example, PO Vancomycin, SC
1 1.25 3.9 2 2.0 2.3 3 3.4 2.5 4 5.5 2.0 6 5.6 3.9 8 12.4 2.0 9 4.4 2.0 10 6.8 5.0 11 14.0 2.0 Table 2 In Vitro Activity Against M. tb and M. avium MICA MIC'' MICA
COMPOUND M. tuberculosis M. avium M. avium EXAMPLE NO. 91-2225$ Lowell Young LPR
1 0.5 1.0 4.0 2 0.5 2.0 4.0 ISONIAZID~ <_0.015 Not done Not done AZIT ~OMYCI Not done 4.0 8.0 A The lowest concentration of drug required to kill the organism or inhibit its growth in vitro.
B Strain designation ~ Isoniazid is a control drug for the tuberculosis test and azithromycin is a control drug for the mycobacterium avium test.
The in vitro activity reported in Table 2 was conducted by standard dilution methods known to those skilled in the art. Briefly, serial two-fold dilutions of antibiotic are prepared in a diluent, and a standard volume of mycobacterial growth medium is added to drug aliquot. The medium is inoculated with a standardized mycobacterial cell suspension, and then incubated under appropriate conditions.
SUBSTITUTE SHEET (RULE 26~
PCT/US94l08904 WO 95/07271 2 ~ 6 s 5 6 0 Following incubation, the Minimal Inhibitory Concentration (MIC) is determined by visual observation. The MIC is defined as the lowest drug concentration (in pg/ml) required to inhibit mycobacterial growth.
Table 3 In vivo Antimycobacterial Activity COMPOUND Logy Colony-Forming EXAMPLE NO. Units of Mycobacterium tuberculosis Per Organ's Drug Treatment Spleen I Lung ~
NoneB 7.72 8.47 IsoniazidC 4.36 3.81 4 5.24 5.03 1 4.61 3.59 A Organ-count enumeration of viable M. tuberculosis was conducted following 1 month therapy of infected mice.
B Infected but not treated animals which served as the negative (untreated) control.
~ Isoniazid (positive control drug) was dosed at 25 mg/kg orally while the three test drugs were dosed at 100 mg/kg.
The in vivo data for Table 3 was obtained from CD-1 mice infected intravenously with 1 x 107 viable M. tuberculosis (Erdman strain). Twenty-four hours later drug treatment was initiated. All the drugs were given by oral gavage twice daily for four weeks. At the end of therapy, viable cell counts were determined from homogenates of spleens and lungs.
EXAMPLE 1: (~)-N-ff3-f3-tlLOro-4-(4-thiomornholi 'y~yhgavll-2-~~~.-~-Ste 1:' ! ~ - u~m-4-mtr~nhenvl)thiomorp The 3,4-difluoronitrobenzene (2.09 mL, 18.857 mmol) was dissolved in dry CH3CN (50 mL) and then treated dropwise with N,N-diisopropylethyl amine (8.212 mL, 47.143 mmol). The resultant yellow mixture was next treated with thiomorpholine (4.74 mL, 47.143 mmol). The reaction was heated to reflux (85°C) for 16 hours and then it was allowed to cool to ambient temperature over 3 hours, stirring under N2. At this point, the reaction was determined to be complete by TLC (15% EtOAcJhexane, UV short wave). The reaction mixture was first concentrated under reduced pressure and then adsorbed onto silica gel (50 g).
The material was chromatographed on more silica gel ( 175 g, packed with hexane), ~UBS'~ITUTE SHEET RULE 26~
a eluting with 1 L each of 5%, 10% and 15% EtOAc/hexane to give 4.6 g (100%) of the title compound as an orange, crystalline solid with a melting point of 59.5-60.5°C
and a HRMS (M+) calculated for C1~H11N202FS 242.0522, found 242.0525.
Step 2: 4-f2-fluoro-4-(benzvl, oxycarbon, 1)~B,~yllthiomon h~ oL_n_e The 4-(2-fluoro-4-nitrophenyl)thiomorpholine (3.67 g, 8.255 mmol) was dissolved in THF (75 mL) and then treated with a solution of sodium hydrosulfite (26.4 g, 151.56) in water (150 mL). The reaction was slightly exothermic.
After an hour, the reaction was found to be complete by TLC (30% EtOAc/hexane, UV short wave). After cooling to 0 °C in an ice bath, the reaction was quenched with NaHC03 (25.5 g, 303.12 mmol). Next, the reaction was diluted with pH 7 buffer (500 mL). After this solution was saturated with solid NaCI, the product was extracted into CH2C12 (4 x 500 mL). The combined extracts were dried over anhydrous Na2S04, filtered and then concentrated under reduced pressure to yield a yellow solid that was stored in the freezer overnight ( 16 hours). The crude amine ( 1.826 g, .8.601 mmol) was dissolved in dry THF (85 mL) and then cooled to -20 °C
(MeOH/ice bath). The solution was treated with N,N-dimethylaniline ( 1.36 mL, 10.75 mmol) and then allowed to stir at -20 °C for 15 minutes. Next, benzylchloro-formate [1.42 mL (corrected for 95% purity), 9.46 mmol] was added dropwise. A
precipitate formed almost immediately. The reaction was allowed to stir for an additional 15 minutes before the bath was removed. Upon warming to mom temperature under N2 ( 1 hour), the reaction was found to be complete by TLC
(30%
EtOAcJhexane, UV short wave). The reaction was diluted with EtOAc (200 mL) and then washed with both water (2 x 200 mL) and brine (200 mL). The aqueous portions were combined and then back-extracted with more EtOAc (2 x 200 mL).
The organic portions were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to yield a yellowish solid. This crude material was chromatographed on silica gel (150 g, packed with 5% EtOAcJhexane), eluting with 2 L of 5% EtOAc/hexane, 1 L of 10% EtOAc/hexane (CH2C12 was added to maintain solubility) to give 2.65 g (50%) of the title compound as an off white crystalline solid with a melting point of 142°C and a HRMS (M+) calculated for C18H19N202FS 346.1151, found 346.1157.
Step 3: ~,)-f3-f3-fluoro-4-(4-thiomornholinyl)phenvll-2-oxo-5-oxazoLdiyLll methanol The 4-[2-fluoro-4-(benzyloxycarbonyl)aminophenyl]thiomorpholine (2.0 g, 5.77 mmol) was dissolved in dry THF (55 mL) and then cooled to -78 °C (dry ice/acetone bath). This solution was treated with the dropwise addition of n-butyllithium over 6 WO 95/07271 ; PCT/LTS94/08904 minutes. The mixture was stirred at -78 °C for 30 minutes and then treated with (R)-(-)-glycidylbutyrate (0.85 mL, 6.0 mmol) dropwise over 2 minutes. The reaction was stirred at -78 °C for an additional 30 minutes before the ice bath was removed.
The reaction was allowed to warm to ambient temperature, stirnng under N2 overnight (16 hours). At this time, the reaction was determined to be complete by TLC (5% MeOH/CHC13, W short wave). The reaction was diluted with CH2C12 (250 mL) and then washed with both water (3 x 200 mL) and brine (200 mL). The aqueous portions were then back-extracted with more CH2C12 (3 x 150 mL). The organic portions were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to yield a yellow solid. This crude material was chromatographed on silica gel (175 g, packed with 10% CH3CN/CHC13), eluting with a gradient of 1-3% MeOH in 10% CH3CN/CHC13 to give 1.583 g (88%) of the title compound as an ofI=white solid with a melting point of 136-137 °C
and a HRMS
(M+) calculated for C14H17N203FS 312.0944, found 312.0942.
Step 4: (R)-ff3-f3-fluorn-4-(4-thiomorn olir~vl)nhenyll-2-oxo-5-oxazolidinyll The [3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methanol ( 1.465 g, 4.69 mmol) was dissolved in pyridine ( 15 mL) and then cooled to 0 °C (ice bath). This solution was next treated withp-toluenesulfonyl chloride (1.34 g, 7.035 mmol) and allowed to stir at 0°C under N2 for 7 hours. At this point, the reaction was stoppered and stored in the freezer overnight ( 16 hours). In the morning, the reaction showed only a trace of starting material by TLC (5% MeOH/CHC13, tJV
short wave). The product was precipitated by quenching the reaction mixture with ice water ( 100 mL). The solid was isolated by suction filtration and washed thoroughly with water. The title compound, 2.02 g (92%), was recovered as a white solid with a melting point of 141°C and a HRMS (M+) calculated for C21H23N205FS2 466.1032, found 466.1036.
Step 5: (l~,)-ff3-(3-fluoro-4-(4-thiomoroholinvl)nhenyll-2-oxo-5-oxazolidinyll methvllazide The [[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl] p-toluenesulfonate (2.0 g, 4.287 mmol) was dissolved in dry DMF ( 15 mL) and then treated with solid NaN3 ( 1.67 g, 25.722 mmol). The reaction was heated to 65 °C
(external temperature) for 6 hours, after which the reaction was allowed to cool to ambient temperature, stirring over a long weekend (158 hours). At this point, the reaction was found to be complete by TLC (6% CH3CN/CHCl3, UV short wave). The reaction was diluted with EtOAc (300 mL) and then washed with water (3 x 250 mL). The aqueous portions were back-extracted with more EtOAc (2 x 150 mL).
The EtOAc portions were combined, dried over Na2S04, filtered and concentrated under reduced pressure to give 1.447 g (100%) of the title compound as an off white solid with a melting point of 91.5-93 °C and a HRMS (M+) calculated for C14H16N505FS 337.1009, found 337.1009.
Step 6: (S)-N-f f 3-f 3-fluoro-4-(4-thiomoroholinyl) enyll-2-oxo-5-oxazolidinvll methyllacetamide The crude [[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]azide (889 mg, 2.635 mmol) was dissolved in dry THF ( 15 mL) and treated with triphenylphosphine (864 mg, 3.294 mmol). After an hour, the reaction was found to be complete by TLC ( 10% MeOH/CHC13, W short wave). Next, water (0.949 mL, 52.7 mmol) was added and the reaction was heated to 50 °C
for two hours. At this point, the reaction was incomplete; so more water (0.475 mL, 26.35 mmol) was added and the reaction was heated to 60 °C for 5 hours.
The reaction was then allowed to cool to ambient temperature, stirring overnight ( hours) under N2. In the morning, the reaction was found to be complete by TLC
( 10% MeOH/CHCl3, W short wave). The reaction was concentrated and then dried under high vacuum for two hours. Next, the semi-solid was dissolved in CH2Cl2 ( 15 mL) and treated with pyridine (0.320 mL, 3.953 mmol). The reaction was allowed to stir for 15 minutes and then the acetic anhydride (0.497 mL, 5.270 mmol) was added dropwise. After an hour, the reaction was complete by TLC (10% MeOH/CHC13, UV
short wave). The reaction mixture was diluted with CH2C12 (50 mL) and then washed with 1 N HCl (50 mL), saturated NaHC03 (50 mL), and brine (50 mL).
Each aqueous portion was back-extracted with more CH2C12 (2 x 20 mL each). The organic portions were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to yield a white solid. This crude material was chromatographed on silica gel (100 g, packed with 10% CH3CN/CHC13), eluting with 1-2% MeOH in 10% CH3CN/CHC13 to give 667 mg (72%) of the title compound as a white solid with a melting point of 185.5-186.5 °C and a HRMS (M+) calculated for C lgH2pN303FS 353.1209, found 353.1200.
EXAMPLE 2: (S)-N-f f ~-f ~-fluoro-4-( 1.1-dioxothiomoroholin-4-~nhenvll-2-oxo-The N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]
acetamide (280 mg, 0.792 mmol) was slurried in 25% water/acetone solution (12 mL) and then treated with solid 4-methylmorpholine N-oxide (278 mg, 2.376 mmol).
~'~ ~~550 Next, the osmium tetroxide in 2-methyl-2-propanol (0.037 mL of a 2.5%
solution, 15%) was added dropwise. The reaction was allowed to stir for 16 hours under at room temperature. At this time, the reaction was determined to be complete by TLC ( 10% MeOH/CHCl3, LTV short wave). The reaction mixture was quenched with saturated sodium bisulfate ( 15 mL) and then extracted into CH2C12 (4 x 25 mL).
The combined organic layers were then washed with more saturated sodium bisulfite ( 100 mL) and brine ( 100 mL). These aqueous portions were back-extracted with more CHZC12 (2 x 50 mL). All of the organic layers were combined, dried over anhydrous Na2S04, filtered and then concentrated under reduced pressure to yield an off white solid. This solid was adsorbed onto silica gel (2.5 g) and chromatographed on more silica gel (30 g, packed with 10% CH3CN/CHC13), eluting with a gradient of 1-5% MeOH in 10% CH3CN/CHC13 to give 224 mg (73%) of the title compound as a white solid with a melting point of 202-203 °C and a HRMS
(M+) calculated for C16H201V3O5FS 385.1108, found 385.1102.
EXAMPLE 3: SS)-N-ff3-f3-fluoro-4-(1-ozothiomornholin-4-vl)~rhenvll-2-oxo-5-Sodium metaperiodate (42 mg, 0.196 mmol) was dissolved in water ( 1 mL) and then cooled to 0 °C (ice bath). Next, the N-[[3-[3-fluoro-4-(4-thiomorpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (66 mg, 0.187 mmol) was added.
Methanol (3 mL) was added to increase solubility. The reaction was stirred at 0 °C
for an additional 4 hours under N2 before being stoppered and stored in the freezer (65 hours). The reaction was filtered through a medium-porosity sintered glass funnel, rinsing the flask and filter cake with CHCl3 (5 mL). The filtrate was transferred to a separatory funnel, the layers separated, and the water layer further extracted with more CHC13 (3 x 5 mL). The organic layers were combined, dried over anhydrous Na2S04, filtered and then concentrated under reduced pressure to yield 80 mg of a gummy solid. The material was chrnmatographed on silica gel (10 g silica, packed with 10% CH3CN/CHCIg), eluting with a gradient of 1-5%
MeOH
in 10% CH3CN/CHCl3 to give 49 mg (71%) of the title compound as an ofd white solid with a mp of 159-161 °C and a HRMS (M+) calculated for C16H2~N3O4 FS 369.1158, found 369.1182.
EXAMPLE 4: (S1-N-[(3-(3.5-di8uoro-4-(4-morpholinyl)ijphenylj-2-ozo-5-ozazolidinvll methyll-acetamide Step 1: 3.5-difluoro-4-~4-morpholinvl)-nitrobenzene To a solution of 1.468 g of morpholine and 3.0 mL of diisopropylethylamine in 80 mL of acetonitrile was added a soluton of 5.019 g of 2,6-difluoro-4-nitrobenzene (trifluoromethane) sulfonate in 10 mL of acetonitrile. The mixture was heated to reflux for 5 hours, then cooled and concentrated in vacuo. The residue was purified on a silica gel column (3 cm tall, 10 cm diam), eluting with 25% ethyl acetate/hexanes (v/v) and then 2% acetic acid/25% ethyl a~etate/hexanes to give 1.95 g of an orange oil. This was washed with 5% ethyl acetate/hexanes, and the bright yellow solids air dried, mp 91-92 ° C.
Step 2: 3.5-difluoro-4-(4-morpholinyl)-aniline A flask containing a solution of 0.203 g of 3,5-difluoro-4-(4-morpholinyl)-nitrobenzene in 5 mL of ethyl acetate was alternately evacuated and filled with nitrogen three times, then 50 mg of 105 palladium on carbon was added and the fask again evacuated and filled with nitrogen then with hydrogen via a balloon (three times). The mixture was stirred at 20 ° C for a total of 2 hours, then filtered over diatomaceous earth an concentrated in vacuo to give an off white solid, Rf =
0.24 (25% ethyl acetate/hexanes, v/v).
Step 3: N~- ~rbobenzvloxv-3.5-difluoro-4-(4-morpholinyl) aniline To a solution of 0.518 g of 3,5-difluoro-4-(4-morpholinyl)-aniline and 0.432 g of sodium bicarbonate in 20 mL of acetone : water (2:1 v/v) at 0°C was added 0.36 mL of benzyl chlorofonmate over 2 minutes. After 5.5 hours, the mixture was allowed to warm to ambient temperature and after an additional 2.6 hours, the mixture was added to 25 mL
of ethyl acetate and 20 mL of brine. The aqueous layer was extracted with 3 x ZS ml of ethyl acetate and the combined organic layers were dried (MgS04), and concentrated in vacuo to give a solid, mp =
131-133 °C.
Step 4: ~R~N-[[3-[3.5-difluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidin~l]
methanol To a solution of 0.195 g of N-carbobenzyloxy-3,5-difluoro-4-(4-morpholinyl) aniline in 5.0 mL of freshly distilled tetrahydrofiuan at -78°C under nitrogen was added 0.36 mL of 1.6 M n-butyl lithiumlhexane and the mixture stirred for 1.5 hours. At that time 0.10 mL of (R)-glycidyl butyrate was added, and after ~e hour, the flask was removed from the dry ice bath, and allowed to come to ambit temperature. After an additional 2 hours, to the solution was added 2 mL of saturated aqueous ammonium chloride and 5 mL of ethyl acetate, then enough water to make the aqueous layer homogeneous. The separated aqueous layers were extracted with ethyl acetate, then dried (MgS04) and concentrated in vacuo to give a yellow solid. This residue was chromatographed on a 24 cm x 2.5 cm column of silica gel 40-63 ~cm, eluting with a gradient of ethyl acetate/hexane (50%-100%), then with 10-20% methanoUethyl acetate, to give a white solid, mp =123-125 °C.
Step 5: jltl-N f j3~3.5-difluoro-4-(4-morpholinlrl)]phenyl]-2-oxo-5-oxazolidinyl]methanesulfonate To a solution of 0.097 g of (R)-N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methanol and 0.10 mL of triethylamine in 5.0 mI, of methylene chloride at 0 ° C was added 0.030 mL of methanesulfonyl chloride, and after 30 minutes, the flask was removed from the ice bath and allowed to come to ambient temperature. The mixture was concentrated in vacuo, and partitioned between water and ethyl acetate, and the aqueous layer extract with ethyl acetate, and the combined organic layers were dried (MgSO,,) and concentrated in vacuo to give a white solid, Rf = 0. 5 S (ethyl acetate).
Step 6: (Rl-N [(3-j3.5-difluoro-4-(4-morpholinyll)phenYlj-2-oxo-5-oxazolidinyl]
girl]azide To a solution of (R)-N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]
methanesulfonate (0.082 g) in 3.0 mL of dimethylfonmamide was added 0.069 g of sodium azide, and die mixture heated at 60 ° C overnight. The mixture was cooled and concentrated in vacuo, maintaining the apparatus behind a safety shield, to give a white solid. This residue was take up in water and ethyl acetate and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine, then dried (MgS04), and concentrated to give a colorless oil, Rf = 0.29 ( 1:1 v/v ethyl acetate/hexane).
Step 7: ~S~N-[[3 j3.5-difluoro-4-(4-morgholinyll]phen~rl]-2-oxo-5-oxazolidiml]meth~~acetamide The flask containing a solution of 0.632 g of (R)-N-[[3-[3,5-difluoro-4-(4-morpholinyl)]phemrl]-2-oxo-5-oxazolidinyl] methyl]azide in 35 mL of ethyl acetate was evacuated and filled with nitrogen (three times). Then 0.116 g of 10%
palladium/carbon was added and the flask again evacuated and filled with nitrogen (three times), then with hydrogen from a balloon (three times). The mixture was stirred for 3.3 hours, then evacuated and filled with nitrogen (three times), and 3.0 mL of pyridine and 2.0 mL of acetic anhydride were added.
After a period of 40 minutes, the mixture was filtered over diatomaceious earth, and the filtrate concentrated in vacuo overnight. The residue of pink solids was recrystallized from hot ethyl acetate/hexane to give a solid. This was chromatographed on a 2.5 cm x 26 cm 40-63 ~cm silica gel column, eluting with a gradient of 0-10% methanoUethyl acetate (v/v); the combined proper fractions gave a solid which was triturated with ethyl acetate/hexanes (1:1, v/v) to give a white solid, mp =195-198°C.
EXAMPLE 5: (S~~N-Q3-[3-8uoro-4-(4-morpholinyl~jphenyll-2-ozo-5-ozazolidinyl] methy,acetamide Step 1: 3-fluoro-4-(4-mor~holinyll-nitrobenzene To a solution of 19.9 g of morpholine, 28.7 g of 3,4-difluoronitrobenzene, and 14.8 g of diisopropyl ethylamine in 100 mL of ethyl acetate was heated at reflux under nitrogen for 4 h.
The mixture was allowed to cool to room temperature overnight, then 100 mL of ethyl acetate, 150 mL of methylene chloride, and 150 mL of water were added, and the aqueous layer extracted with 2 x 50 mL of methylene chloride and 50 mL of ethyl acetate. The combined organic layers were dried (NazSO,) to give a yellow solid. This was recrystallized from acetone-water to give a yellow solid, mp = 112-113 °C.
Step 2: 3-fluoro-4-(4-mor~holin_yl)-aniline To a suspension of 36.56 g of 3-fluoro-4-(4-morpholinyl)-nitrobenzene and 48.84 g of ammonium formats in 110 mL of tetrahydrofuran and 440 mL of methanol under nitrogen was added 0.524 g of 10% palladium/carbon. After stirring the mixture for a total of 3 hours, the mixture was filtered through diatous earth, and the filter pad was washed with ethyl acetate. The filtrate was concentrated to a volume of about 450 mL and then 200 mL of water was added. This was extracted with 300 mL of ethyl acetate, then the organic layer was washed with 2 x 150 mL of water and then 200 mL of brine, dried (MgS04), and concentrated to give a brown solid, Rf~.47 (1:1 ethyl acetate/hexanes, v/v).
Step 3: N-carbobenzvloxv-3-fluoro-4-(4 morpholinyl) aniline To a solution of 28.91 g of 3-fluoro-4-(4-morpholinyl)-aniline and 27.88 g of sodium bicarbonate in 500 mL of acetone and 250 mL of water at 0°C was added 28.68 g of benzyl chloroformate. After stirring the mixture for 1.5 hours, the mixture was poured onto 1000 cc of ice and water, and the ice allowed to melt. The precipitated solid was collected by filtration and washed with 3 x 250 ml of water, and then dried in a vacuum oven at 75 °C to give a gray-purple solid. This was recrystallized from acetone-water to give a cream-colored solid, mp =123-124°C.
Step 4: (RAN-[[3-[3-fluoro-4-r(4-morpholinyl,)]~yl)-2-oxo-5-oxazolidin~l methanol To a solution of 39.01 g of N-carbobenzyloxy-3-fluoro-4-(4-morpholinyl) aniline in 550 mL of freshly distilled tetrahydrofuran at -78 °C under nitrogen was added 77 mL of 1.6 M n-butyl lithium/hexane via syringe over 30 minutes, and the mixture stirred for an additional 40 minutes. At that time, a solution of 18.32 g of (R)-glycidyl butyrate in 30 mL
of tetrahydrofuran was added over 30 minutes, and after 1.5 hours, the flask was removed from the dry ice bath, and allowed to come to ambient temperature. After stirring the mixture overnight, 20 ml of saturated aqueous ammonium chloride was added, followed by 500 mL of water, and the aqueous layer extracted with ethyl acetate (4 x 300 mL). The combined organic layers were washed with 200 mL of brine and dried (MgS04) to give light purple solid. This is triturated with 1200 mL of l:l ethyl acetate/hexanes (v:v), then recrystallized from ethyl acetate/hexanes to give a white solid, mp =110-113 °C.
Step 5: fR)-N-f [3-[3-fluoro-4-C4-morpholinvl)] eml]-2-oxo-5-oxazolidinvl]
methanesulfonate To a solution of 13.28 g of (R)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinylJ methanol and 8.71 g of triethylamine in 100 mL of methylene chloride at 0°C
under nitrogen was added 7.4 g of methanesulfonyl chloride over 4 minutes. The mixture was allowed to stir at 0°C for 30 minutes, then allowed to warm to ambient temperature. At white solid was a precipitated. Water (175 mL) and 650 mL of methylene chloride and 100 mL of ethyl acetate were added, but the solid did not all dissolve, therefore the mixture was filtered to give a shits solid. Additional material was recovered from the filtrate by multiple extraction of the aqueous layer with methyle~ne chloride. The white solid was dried in a vacuum oven, mp =
183-184 °C.
Step 6: ~Rl-N-[(3 j3-fluoro-4-(4-morcrholinyl)Jpher~rl]-2-oxo-5-oxazolidinyl]
methyl]azide To a solution of (R)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]
methanesulfonate (9.05 g) in 200 mL of dimethylformamide was added 6.367 g of sodium azide, and the mixture heated at 85°C overnight. The mixture was cooled and poured into 500 mL of water and 150 mL of ethyl acetate. The aqueous layer was extracted with 2 x 75 mL of ethyl acetate, and the combined organic layers were dried (MgSO,), and concentrate by vacuum distillati~ to remove the bulk of the dimethylformamide. The brown oil, containing some dimethylformamide, was utilized without further purification, Rf = 0.74 ( 10%
methanoUethyl acetate v/v).
Step 7: (,S')-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyll-2-oxo-5-oxazolidinyl]meth~rltacetamide A flask containing the crude azide (R)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2 21b8560 oxo-5-oxazolidinyl]methyl]azide (assume 24.2 mmol) in 500 mL of ethyl acetate was evacuated and filled with nitrogen (three times). Then 0.602 g of 10%
palladium/
carbon was added and the flask again evacuated and filled with nitrngen (three times), then with hydrogen frnm a balloon (four times). The mixture was stirred for 17 hours, then a fresh balloon of hydrogen was attached. After a period of 5 hours, the flask was evacuated and filled with nitrngen (three times), and 16 mL of pyridine and 10 mL of acetic anhydride were added. After a period of 2.5 hours, the mixture was filtered over diatomaceous earth, washing the pad with ethyl acetate, and the filtrate concentrated in vacuo to give a brown gummy solid. The residue was purified by chrnmatography on a 5.5 cm x 25 cm 40-63 um silica gel column, eluting with a gradient of 2-10% methanol/ethyl acetate (v/v); the combined proper fractions gave an off white solid, which was triturated with ethyl acetate and dried to give an o$' white solid, mp = 181.5-182.5°C.
EXAMPLE 6: (S)-N-f f3-f3-fluoro-4-f 1-f (m-toluenesulfonvDiminol The N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl]acetamide (213 mg, 0.603 mmol) was dissolved in dry CH2C12 (11.5 mL) and then treated with hexadecyl-tributylphosphonium bromide ( 138 mg, 0.271 mmol).
To this clear, colorless solution, the chloramine-T ( 165 mg, 0.723 mmol) was added.
The resultant cloudy solution was stirred at room temperature for three hours.
At this time, the reaction was determined to be complete by TLC ( 10% MeOH/CHC13, UV short wave). The reaction mixture was transferred to a separatory funnel and diluted with CH2C12 ( 10 mL). This solution was washed with cold 5% NaOH (20 mL), water (20 mL), and brine (20 mL). The aqueous portions were combined and then back-extracted with more CH2C12 (3 x 20 mL). The organic layers were combined, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The resultant material was chromatographed on silica gel (100 g), eluting with a gradient of 0-6% MeOH in 10% CH3CN/CHCl3 to give 314 mg (99%) of the title compound as a white solid which decomposes at 79°C and has a HRMS
(FAB) calculated for C23H28FN405S2 (M + H)+, 523.1485, found 523.1477.
EXAMPLE 7: (S)-N-ff3-f3-tluoro-4-4-(3-thiazolidinvDl envll-2-oxo-5-Step 1: 3-(2-fluoro-4-nitrophenvl)thiazolidine Using the same general procedure as step 1, of Example 1, 4.092 g (45.90 mmol) thiazolidine was treated with 4.1 mL (37.03 mmol) 3,4-difluornnitrobenzene and 10.0 mL (57.41 mmol) N,N diisopropylethyl amine to provide 2.020 g (24%) of the title compound as an orange solid. Recystallization from methylene chloride /
hexane provided an analytical sample with a melting point of 94 -95 °C.
Step 2: 3-f2-fluoro-4-(benzvloxvcarbonvl)aminonhenvllthiazolidine The 3-(2-fluoro-4-nitrophenyl)thiazolidine ( 1.485 g, 6.513 mmol) was dissolved in tetrahydrofuran (25 mL) and water (5 mL) and then shaken under 40 psi of hydrogen in the presence of Raney nickel (500 mg) for 5 hours. After this time, the mixture was filtered over diatomaceous earth. The filter pad was washed with methanol and the filtrate was concentrated to an aqueous layer. Water (15 mL) and acetone (25 mL) were added to the aqueous mixture and the mixture was cooled in an ice bath. Solid sodium bicarbonate (2.728 g, 32.47 mmol) was added followed by benzyl chloroformate (3.0 mL, 21.01 mmol). The mixture was allowed to warm to room temperature and stirred over 3 nights. Ethyl acetate was added to the mixture and the layers were separated. The aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried (MgS04 ) and concentrated under reduced pressure to provide 3.925 g crude material as a dark oil. The crude was chromatographed on a silica gel column (27 cm x 4.5 cm, 40 - 63 u), eluting with 500 mL 40% hexane/methylene chloride, 1L 20% hexane/methylene chloride, 500 mL
10% hexane/methylene chloride, 500 mL methylene chloride and 500 mL 3%
methanol/methylene chloride to provide 480 mg of the title compound as yellow solids and 950 mg of the title compound contaminated with benzyl alcohol. In order to remove the benzyl alcohol contaminate, the contaminated material was treated with triethyl amine (0.6 mL, 4.31 mmol), butyric anhydride (0.45 mL, 2.86 mmol) and a small amount of 4-dimethylamino pyridine at 0°C. After 35 minutes the mixture was concentrated and chromatographed on a silica gel column (23.5 cm x 2.5 cm, 40 - 63 u), eluting with 250 mL 10% ethyl acetate/hexane and 500 mL
15%
ethyl acetate/hexane to provide 700 mg of the title compound as light yellow solids.
In all, 1.180 g (59%) of the title compound was obtained. Recrystallization frnm ethyl ether/hexane provided an analytical sample with a melting point of 90 -92°C.
Step 3: (R)-f 3-f 3-fluoro-4-(3-thiazolidinyl)phenvll-2-oxo-5-oxazolidinyll methanol Using the same general procedure as step 3 of example 1, 3-[2-fluoro-4-(benzyloxycarbonyl) aminophenyl]thiazolidine (692 mg, 2.24 mmol) was treated sequentially with n-butyllitium ( 1.5 mL, 2.40 mmol) and (R)-(-)-glycidylbutyrate (0.33 mL, 2.33 mmol) to provide 500 mg (78%) of the title compound.
Recystallization from methylene chloride/hexane provided an analytical sample with w --CA 02168560 2001-05-02 4717.P CP
a melting point of 96 - 97°C.
Step 4: (R) ff3 f3 fluoro 4 (3 thiazolidinyl)phen3~~2-oxo-5-ozazolidiny~llmethvll-(R)-[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl] methanol (300 mg, 1.05 mmol) and triethylamine (0.30 mL, 2.16 mmol) in 15 mL of methylene chloride was cooled in an ice bath and treated with methanesulfonyl chloride (0.10 mL, 1.29 mmol). The mixture was removed from the ice bath and stirred at room temperature for 45 minutes then 10 mL of 1 ~T HCl was added. The resulting layers were separated and the aqueous layer was extracted with methylene chloride.
The combined organic layers were washed with saturated aqueous sodium bicarbonate, dried (MgS04), and concentrated under reduced pressure to provide 342 mg (87%) of the title compound as a yellow solid, Rf--0.58 (ethyl acetate).
Step 5: ~S)-N-ff3-f3-fluorn-4-(3-thiazolidiny11R~1.~1y11-2-oxo-5-oxazoLdinvll The (R)-[[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-ozazolidinyl]methyl]-methanesulfonate (342 mg, 0.910 mmol) was slurried in 5 ml of tetrahydrofuran isopropanol ( 1:1) and treated with 5.0 mL of concentrated ammonium hydroxide in a sealed tube at 85 - 95°C for 6 hours. The mixture was then poured into 20 mL
water and 20 mL methylene chloride. The layers were separated and the aqueous layer was extracted with methylene chloride (3x). The combined organic layers were washed with brine, dried (MgS04) and concentrated under reduced pressure to a yellow oil. The crude was taken up in 20 mL methylene chloride and cooled in an ice bath. The mixture was treated with 0.5 mL pyridine and 0.5 mL acetic anhydride and removed from the ice bath. After stirring of 30 minutes at room temperature, the mixture was concentrated under reduced pressure to an oil.
The crude was chromatographed on a silica: gel column (23 cm x 2.5 cm, 40 - 63 p), eluting with 200 mL 75% ethyl acetate/hexane, 250 mL ethyl acetate and 500 mL
10% methanoUethyl acetate to provide 190 mg of the title compound as a yellow solid (53% yield from (R)-[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]
methanol). Crystallization of the yellow solid from methylene chloride/hexane provided 113 mg of the title compound as a light yellow solid with a melting point of 103 - 105°C.
Step 6: ~S~-N-[(3~3-fluoro-4,~4-morpholinvlllohemrl]-2-oxo-5-oxazc>lidinvllmethvll-h imide 'Ihe methanesulfonate (of Ex. 5, step 5), (32.559 g, 87.0 mmol of compound from Step 5, above) and potassium phthalimide (32.348 g, 174.6 mmol) were weighed wCA 02168560 2001-05-02 4717.P CP
into a flask. Acetonitrile (500 ml) was added, and the mixture was refluxed under nitrogen atmosphere for 2 days, and was stirred at room temperature over the weekend. The reaction mixture, which contained a white precipitate, was filtered.
The solid was carefully washed with acetonitrile. The filtrate was then evaporated to give the desired product, as a yellow solid (22.$07 g). Because of the poor recovery, the white solid was stirred with 600 ml of acetonitrile overnight.
It was then filtered. The solid was again carefully washed with more acetonitrile.
The solvent was evaporated to give the desired compound, (7.964 g). This extraction process was repeated and an additional 4.408 g of product was obtained (35.179 g total). The crude material was recrystallized from acetone and water in several batches ( 13.138 g, boiling, 800 ml acetone, 900 ml water, cooled to room temperature) to give 31.745 g (86%) of the product, as white crystals in "first crops"
along with 2.004 g (5%) in "second crops".
Melting Point: 199-200 °C.
Mass Spectrum: m/e (rel. abundance): 425 (100, M+), 426 (25.6), 186 (23.9), (14.5), 175 (16.4), 160 (27.1), 150 (18.9), 149 (16.1), 148 (11.5), 77 (11.4);
exact mass calc'd for C22H20FN305~ 425.137. Found: 425.1387.
Analysis calc'd for C22H20FN305~ C, 62.11; H, 4.74; N, 9.88. Found: C, 62.06;
H, 4.78; N, 9.88.
Specific Rotation: [a]D -57° (c 0.834, CHC13).
Step 7: (Sl N ff3 [3 fluoro-4 4 morehol' )loheny~l-2-oxo-5-oxazolidinvllmethyllamine Ethanol (320 ml) and aqueous methylamine (30 ml of 40%, 386.3 mmol) were added to a flask containing the phthalimido oxazolidinone, from Step 6, (27.013 g, 63.5 mmol). The suspension which was placed under nitrogen atmosphere, was heated at 70 °C for 3 hr, and refluxed for 1 hr. A 55 ml aliquot was removed for purification (the remainder was converted to the acetamide U-100766). This was purified in two batches, on a medium pressure silica column (40 x 63 u, 4.2 cm x 28 cm, packed with 3% methanol/methylene chloride, eluted with 500 ml 3%, 2000 ml 5%, 1000 ml 10% methanol/methylene chloride, collected 50 ml fractions) to give 3.681 g of the amine, the title compound, as a white solid.
mp 103-104 °C.
Mass Spectrum: m/e (rel. abundance): 295 (100, M+), 237 (8.9), 222 (10.5), 209 (29.4), 164 (28.6), 151 (53.9), 150 (20.5).
Analysis calc'd for C14Hi8FN303: C, 56.94; H, 6.14; N, 14.23. Found: C, 56.56;
H, 6.24; N, 14.05.
.. . _.. __ _.. _... .... .__ _--_ ...... CA 02168560 2001-05-02 4717.P CP
Step 8: jS'~[(3-[3-fluoro-4-~4-morpholin3rl)]phernrlj-2-oxo-5-oxazolidin~rl]methyl]-benz5rloxyacetamide A solution of the aminomethyl oxazolidinone, from Step ?, (0.201 g, 0.68 mmol) in 5 ml of pyridine was cooled to 0 °C under nitrogen atmosphere.
Then benzylosyacetyl chloride (0.13 ml, 0.82 mmol) was added uia syringe. The reaction mixture was stirred for 24 hr as it gradually warmed to ambient temperature.
The solvent was then evaporated and the residue was purified on a medium pressure silica column (43 x 60 u, 2.4 cm x 26 cm, packed with 5% methanoUmethylene chloride, eluted with 5% and 10% methanoUmethylene chloride, 15 ml fractions were collected) to give 0.296 g (98%) of the improved quality material as a white solid. A
portion of this solid (0.053 g) was recrystallized from methylene chloride and hexanes to give 0.036 g of the desired material as white crystals, mp 104.5-106 °C.
Mass Spectrum: m/e (rel. abundance): 443 (100, M+), 399 (14.2), 234 (28.3), (16.8), 196 (10.1), 176 (9.3), 164 (13.2), 150 (10.6), 91 (60.2).
Analysis calc'd for C23H26FN305~ C. 62.29; H, 5.91; N, 9.47. Found: C, 62.04;
H, 5.93; N, 9.37.
EXAMPLE 8: ~~'~-N [[3-13-fluoro-4-(4-mo~avlllnhen~l-2-ozo-5-ozazolidinvll-methvllhvdrozvacetamide The benzyloxyacetamidomethyl oxazolidinone, product of Step 8 from Example 7, (0.163 g, 0.37 mmol) was dissolved in ethyl acetate ( 10 ml) and methanol (1 ml) and was placed under nitrogen atmosphere by alternately evacuating and fi11~ the system with nitrogen 3x. Then 10% palladium on carbon (0.050 g) was added and the system was again evacuated and filled with nitrogen 3x. Hydrogen was then introduced into the system 2x uia a hydrogen balloon. The reaction mixture was stirred over a weekend. The reaction mixture was then filtered through diatomaceous earth which was carefully washed with 5% methanol/ethyl acetate. The solvents were evaporated to~give 0.120 g of crude material which vas purified on a medium pressure silica column (43 x 60 u, 1.6 cm x 27 cm, packed and eluted with 10% methanol/methylene chloride, collected 10 ml fractions) to give 0.026 g (20%) of the desired product as a white solid, mp 114-115 °C.
Mass Spectrum: m/e (rel. abundance): 353 (100, M+), 309 (20.7), 234 (28.4), (7.6), 209 (21.8), 196 ( 10.2), 176 (24.9), 164 ( 17.4), 151 ( 14.9), 138 ( 19.0), 101 ( 12.5), 56 ( 16.8), 43 ( 18.0).
TLC: 10% Methanol/Methylene Chloride: Rf = 0.39.
4717.P CP -26-EXAMPLE 9: fS'~(j3-j3-tluoro-4-(4-morpholinYl)jphenyl]-2-oao-5-oaazolidinvll-methyl]formamide Acetic anhydride (0.35 ml, 3.7 mmol) was added to a formic acid (2 ml, 53 mmol) solution of the aminomethyl oxazolidinone, product of Step 7 from Example 7, (0.199 g, 0.67 mmol). This solution was stirred under nitrogen atmosphere for two weeks. Then, although there was still evidence of starting material by TLC, the reaction mixture was evaporated. The residue was purified on a medium pressure silica column (43 x 60 u, 2.4 cm x 25 cm, packed and eluted with 5%
methanol/methylene chloride, 15 ml fractions were collected) to give 0.162 g (74%) of the desired material as a white foamy solid, mp 44-47 °C.
Mass Spectrum: m/e (rel. abundance): 323 ( 100, M+), 279 (5.9), 265 (6.7), 234 (11.1), 221 (6.5), 209 (6.8), 176 (13.2), 164 (8.3), 151 (13.0), 138 (8.6).
EXAMPLE 10: (S'~N-((3-(3-fluoro-4-(4-morpholin~rl)]phenyl]-2-oao-5-oaazolidi~ll-methyl]methvlcarbamate A methylene chloride solution (2 ml) of the aminomethyl oxazolidinone, product of Step 7 from Example 7, (0.209 g, 0.71 mmol) was cooled to 0 °C under nitrogen atmosphere. Triethylamine (0.12 ml, 0.86 mmol) and methyl chloroformate (0.25 ml, 3.23 mmol) were added. The reaction mixture gradually warmed to ambient temperature. After stirring 4.5 hr, the solvent was evaporated to give a foamy pink solid. This residue was purified on a medium pressure silica column (43 x 60 u, 2.4 cm x 25 cm, packed and eluted with 5% methanol/methylene chloride, collected 15 ml fractions) to give 0.188 g of the desired product as a white solid. The upgraded product was then recrystallized from methylene chloride and hexanes to give 0.168 g (67%) of white crystals, mp 147.5-148.5 °C. Another 0.018 g (7%) of the desired compound was isolated in a subsequent recrystallization.
Mass Spectrum: m/e (rel. abundance): 353 ( 100, M+), 295 (4.3), 234 ( 14.6), (6.7), 209 (6.7), 176 (16.6), 164 (14.0), 150 (10.6), 138 (13.7), 114 (4.8), 88 (6.1), 43 ( 10.9).
Specific Rotation: [a]D -14° (c 0.844, CHCl3).
4717.P CP -27-EXAMPLE 11: (S)-N-(f3-13-fluoro-4-l4-mo holin~I~lghenvl~-2-oao-5-oaazolidinvll meth~rl]dichloroacetamide A methylene chloride solution (2 ml) of the aminomethyl oxazolidinone, product of Step 7 from Example 7, (0.200 g, 0.68 mmol) was cooled to 0 °C under nitrogen atmosphere. Then triethylamine (0.11 ml, 0.79 mmol) was added.
Dichloroacetyl chloride (0.11 ml, 1.14 mmol) was then added slowly vizz syringe over 3 min, some gas evolved. The reaction mixture slowly came to ambient temperature as it stirred overnight. The solvent was evaporated and the residue was purified on a medium pressure silica column (43 x 60 p, 2.5 cm x 27 cm, packed and eluted with 2% methanol/methylene chloride, collected 15 ml fractions) to give 0.140 g (51%) of the desired material as a light tan solid, mp 193-196 °C.
Mass Spectrum: m/e (rel. abundance): 407 (M+2+, 64.9), 405 (M+, 100), 176 ( 12.3), 164 (18.1), 151 (26.7), 150 (18.7), 149 (17.8), 138 (19.6).
Analysis calc'd for C 16H 18C12FN304: C, 47.31; H, 4.4?; N, 10.34. Found: C, 47.12; H, 4.67; N, 10.20.
Specific Rotation: [a]D -36° (c 0.955, CHC13).
R' Rz R~ Rz X~ H ~ Y ~ ~ NOz X' N ~ ~ NOz ~CHz~ n Rz - ~CHz ~ n Rz R/ \ R: R~ Rz O
X N ~ ~ NHz X' N ~ ~ "OR, ~CHz ~ n Rz - ~--~CFIz ~ x -n R
R~ Rz ~ O R' Rz O
X/ N . ~ ~ N ~0 X~ ~ \ N ~0 .
~CHz~n Rz- ....H ~--~CHz~n z- ..,.H
OH R ORS
R~ Rz O R~ Rz 0 X N ~ ~ N- 'O X N ~ ~ N- 'O
~--~CHH ~n .'..H CH n "H O
z Rz- ~Rt z Rz- ~ _C_R
Rx O Rx 0 O= ~ ~ ~ N"O ~ ~ ~ ~ N~O
~CHx,~ R - ..,.H O O ~--~CHx~~ R - ...,H O
x II x II
-C-R ~-C-R
o Rx o S~ N ~ ~ N~O ~ ~ ~ ~ N~0 '--~CHx~n Rx- "..H O ~N ~CHx~n Rx- ~ 0 p-C-R d p-C-R
Rx 0 ~N= ~ ~ ~ N"O
RIo ~CHx~ ".~H O
n -C-R
Claims (20)
1. A compound of structural Formula I:
or a pharmaceutically acceptable salt thereof wherein:
X is O, S, SO or SO2 R is (a) hydrogen, (b) C1-C8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C1-C8 alkoxy, C1-C8 acyloxy or -O-CH2-Ph, (c) C3-C6 cycloalkyl, (d) amino, (e) C1-C8 alkylamino, (f) C1-C8 dialkylamino or (g) C1-C8 alkoxy;
R1 is H, except when X is O then R1 can be H, CN, CO2H, CO2R or (CH2)m R11 (m is 1 or 2);
R2 is independently H, F or Cl;
R3 is H except when X is O and R1 is CH3 then R3 can be H or CH3;
R11 is hydrogen, OH, OR, OCOR, NH2, NHCOR or N(R10)2;
R10 is independently H, C1-C4 alkyl (optionally substituted with chloro, fluoro, hydroxy, C1-C8 alkoxy, amino, C1-C8 alkylamino, or di-(C1-C8) alkylamino or p-toluenesulfonyl; and n is 0, 1 or 2.
or a pharmaceutically acceptable salt thereof wherein:
X is O, S, SO or SO2 R is (a) hydrogen, (b) C1-C8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C1-C8 alkoxy, C1-C8 acyloxy or -O-CH2-Ph, (c) C3-C6 cycloalkyl, (d) amino, (e) C1-C8 alkylamino, (f) C1-C8 dialkylamino or (g) C1-C8 alkoxy;
R1 is H, except when X is O then R1 can be H, CN, CO2H, CO2R or (CH2)m R11 (m is 1 or 2);
R2 is independently H, F or Cl;
R3 is H except when X is O and R1 is CH3 then R3 can be H or CH3;
R11 is hydrogen, OH, OR, OCOR, NH2, NHCOR or N(R10)2;
R10 is independently H, C1-C4 alkyl (optionally substituted with chloro, fluoro, hydroxy, C1-C8 alkoxy, amino, C1-C8 alkylamino, or di-(C1-C8) alkylamino or p-toluenesulfonyl; and n is 0, 1 or 2.
2. The compound of Claim 1 wherein X is O.
3. The compound of Claim 2 wherein each R2 is fluorine.
4. The compound of Claim 1 wherein n is 1 and X is S, SO or SO2.
5. The compound of Claim 1 which is an optically pure enantiomer having the S-configuration at C5 of the oxazolidinone ring.
6. The compound of Claim 1 wherein one R2 is hydrogen and the other is fluorine.
7. The compound of Claim 1 wherein R is methyl, OCH3, CHCl2, CH2OH or hydrogen.
8. The compound of Claim 1 which is:
(a) (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxothiomorpholin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4-(1-oxothiomorpholin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(d) (S)-N-[[3-[3,5-difluoro-4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(e) (S)-N-[[3-(3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(f) (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]-hydroxyaceramide;
(g) (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazalidinyl]methyl]-formamide;
(h) (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]methyl-carbamate; or (i) (S)-N-[[3-[3-fluoro-4-{4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]-dichloroacetamide;
oxazolidinyl]methyl]dichloroacetamide.
(a) (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxothiomorpholin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4-(1-oxothiomorpholin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(d) (S)-N-[[3-[3,5-difluoro-4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(e) (S)-N-[[3-(3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(f) (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]-hydroxyaceramide;
(g) (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazalidinyl]methyl]-formamide;
(h) (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]methyl-carbamate; or (i) (S)-N-[[3-[3-fluoro-4-{4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]-dichloroacetamide;
oxazolidinyl]methyl]dichloroacetamide.
9. The compound of Claim 1 where n is 0 and X is O, S, SO or SO2.
10. The compound of Claim 9 wherein one R2 is hydrogen and the other is fluorine.
11. The compound of Claim 9 which is:
(a) (S)-N-[[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4(1-oxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; or (d) (S)-N-[[3-[3-fluoro-4-(3-oxazolidinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
(a) (S)-N-[[3-[3-fluoro-4-(3-thiazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4(1-oxothiazolidin-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; or (d) (S)-N-[[3-[3-fluoro-4-(3-oxazolidinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
12. The compound of Claim 1 where n is 2 and X is O, S, SO or SO2.
13. The compound of Claim 12 wherein one R2 is hydrogen and the other is fluorine.
14. The compound of Claim 12 which is:
(a) (S)-N[[3-[3-fluoro-4-hexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxohexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4-(1-oxohexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; or (d) (S)-N-[[3-[3-fluoro-4-(hexahydrooxazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
(a) (S)-N[[3-[3-fluoro-4-hexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(b) (S)-N-[[3-[3-fluoro-4-(1,1-dioxohexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide;
(c) (S)-N-[[3-[3-fluoro-4-(1-oxohexahydrothiazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; or (d) (S)-N-[[3-[3-fluoro-4-(hexahydrooxazepin-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
15. For use in the preparation of a medicament useful in treating a microbial infection in patients, a compound of Formula I as shown in Claim 1.
16. For use in oral, parenteral, or topical treatment of a microbial infection in a patient, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of compound of Formula I as shown in Claim 1.
17. The composition of Claim 16 wherein the amount of the compound of Formula I is about 0.1 to about 100 mg/kg of body weight of the patient.
18. The composition of Claim l6 wherein the amount of the compound of Formula I is about 1.0 to about 50 mg/kg of body weight of the patient.
19. The composition of Claim 16 wherein said microbial infection is caused by staphylococci, streptococci, enterococci, Bacteroides spp., Clostridia spp., Mycobacterium tuberculosis, Mycobacterium avium or Mycobacterium spp..
20. A compound which is:
(S)-N-[[3-[3-fluoro-4-[1-[(p-toluenesulfonyl)imino]thiomorpholin-4-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
(S)-N-[[3-[3-fluoro-4-[1-[(p-toluenesulfonyl)imino]thiomorpholin-4-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11927993A | 1993-09-09 | 1993-09-09 | |
US22615894A | 1994-04-11 | 1994-04-11 | |
US226,158 | 1994-04-11 | ||
US119,279 | 1994-04-11 | ||
PCT/US1994/008904 WO1995007271A1 (en) | 1993-09-09 | 1994-08-16 | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2168560A1 CA2168560A1 (en) | 1995-03-16 |
CA2168560C true CA2168560C (en) | 2001-08-14 |
Family
ID=26817181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002168560A Expired - Lifetime CA2168560C (en) | 1993-09-09 | 1994-08-16 | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0717738B1 (en) |
JP (1) | JP3176630B2 (en) |
KR (1) | KR100301269B1 (en) |
CN (1) | CN1057087C (en) |
AT (1) | ATE185804T1 (en) |
AU (1) | AU687866B2 (en) |
CA (1) | CA2168560C (en) |
DE (2) | DE10299007I2 (en) |
DK (1) | DK0717738T3 (en) |
ES (1) | ES2139093T3 (en) |
GR (1) | GR3031809T3 (en) |
IL (1) | IL110802A (en) |
LV (1) | LV12605B (en) |
MY (1) | MY115155A (en) |
NL (1) | NL300079I1 (en) |
NZ (1) | NZ271805A (en) |
PH (1) | PH31634A (en) |
SI (1) | SI0717738T1 (en) |
TW (1) | TW293817B (en) |
WO (1) | WO1995007271A1 (en) |
Families Citing this family (239)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9703543A (en) * | 1994-11-15 | 1997-08-30 | Upjohn Co | Bicyclic oxazine and thiazine oxazolidinone antibacterials. |
DE69615002T2 (en) * | 1995-02-03 | 2002-06-13 | Pharmacia & Upjohn Co., Kalamazoo | PHENYLOXAZOLIDINONE SUBSTITUTED BY HETERO-AROMATIC RING AS AN ANTIMICROBIAL AGENT |
MX9708627A (en) * | 1995-05-11 | 1998-02-28 | Upjohn Co | Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones. |
ES2185800T3 (en) * | 1995-09-15 | 2003-05-01 | Upjohn Co | ANTIBACTERIAL AGENTS BASED ON 5-AMIDOMETHYL, 3-ARYL BUTIROLACTONE ALPHA, BETA SATURATED AND UNSATURATED. |
DE69631347T2 (en) * | 1995-09-15 | 2004-10-07 | Upjohn Co | AMINOARYL OXAZOLIDINONE N-OXIDES |
GB9521508D0 (en) * | 1995-10-20 | 1995-12-20 | Zeneca Ltd | Chemical compounds |
GB9601666D0 (en) * | 1996-01-27 | 1996-03-27 | Zeneca Ltd | Chemical compounds |
GB9702213D0 (en) | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
MY116093A (en) * | 1996-02-26 | 2003-11-28 | Upjohn Co | Azolyl piperazinyl phenyl oxazolidinone antimicrobials |
GB9604301D0 (en) * | 1996-02-29 | 1996-05-01 | Zeneca Ltd | Chemical compounds |
SK284703B6 (en) * | 1996-04-11 | 2005-09-08 | Pharmacia & Upjohn Company | Process for preparing substituted oxazolidinone alcohols |
GB9609919D0 (en) | 1996-05-11 | 1996-07-17 | Zeneca Ltd | Chemical compounds |
DE19709443C1 (en) * | 1997-03-07 | 1998-10-08 | Clariant Gmbh | Process for the preparation of N-carboxyalkyl-3-fluoro-4-dialkylaminoanilines and N-carboxymethyl-3-fluoro-4-morpholinoaniline and N-carboxyisobutyl-3-fluoro-4-morpholinoaniline |
JP2002501530A (en) | 1997-05-30 | 2002-01-15 | ファルマシア・アンド・アップジョン・カンパニー | Oxazolidinone antimicrobial agents with thiocarbonyl functionality |
US6255304B1 (en) | 1997-05-30 | 2001-07-03 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
GB9717804D0 (en) | 1997-08-22 | 1997-10-29 | Zeneca Ltd | Chemical compounds |
GB9717807D0 (en) | 1997-08-22 | 1997-10-29 | Zeneca Ltd | Chemical compounds |
KR100580408B1 (en) * | 1997-11-07 | 2006-05-16 | 파마시아 앤드 업존 캄파니 엘엘씨 | Process to Produce Oxazolidinones |
GB9725244D0 (en) | 1997-11-29 | 1998-01-28 | Zeneca Ltd | Chemical compounds |
US7002020B1 (en) | 1998-01-23 | 2006-02-21 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
US6562844B2 (en) | 1998-01-23 | 2003-05-13 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
BR9907183A (en) | 1998-01-23 | 2003-06-10 | Versicor Inc | Oxazolidinone combinatorial collections, compositions and preparation processes |
JP2002503655A (en) * | 1998-02-13 | 2002-02-05 | ファルマシア・アンド・アップジョン・カンパニー | Substituted aminophenyl isoxazoline derivatives useful as antibacterial agents |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
WO2000029396A1 (en) * | 1998-11-17 | 2000-05-25 | Bayer Aktiengesellschaft | Novel substituted phenyloxazolidone derivatives |
CA2351062A1 (en) * | 1998-11-27 | 2000-06-08 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
US6608081B2 (en) | 1999-08-12 | 2003-08-19 | Ortho-Mcneil Pharmaceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
US6297242B1 (en) | 1999-08-12 | 2001-10-02 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof |
CN1221548C (en) * | 1999-12-21 | 2005-10-05 | 法玛西雅厄普约翰美国公司 | Oxazolidinones having sulfoximine functionality and their use as antimicrobial agents |
US6518285B2 (en) * | 1999-12-21 | 2003-02-11 | Ortho Mcneil Pharmaceutical, Inc. | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials |
KR100355345B1 (en) * | 2000-01-21 | 2002-10-12 | 한국과학기술연구원 | Oxazolidinone derivatives containing thiophene ring, a preparative method thereof and composition |
AR027261A1 (en) * | 2000-02-02 | 2003-03-19 | Upjohn Co | LINEZOLID CRYSTAL FORM II |
US6642238B2 (en) | 2000-02-10 | 2003-11-04 | Pharmacia And Upjohn Company | Oxazolidinone thioamides with piperazine amide substituents |
US6562820B2 (en) | 2000-07-05 | 2003-05-13 | Pharmacia & Upjohn Company | Method for treatment and prevention of mastitis |
US6638908B1 (en) | 2000-08-09 | 2003-10-28 | Yale University | Crystals of the large ribosomal subunit |
US6947844B2 (en) | 2000-08-09 | 2005-09-20 | Yale University | Modulators of ribosomal function and identification thereof |
ES2256318T3 (en) * | 2000-10-17 | 2006-07-16 | PHARMACIA & UPJOHN COMPANY LLC | PRODUCTION METHODS OF OXAZOLIDINONE COMPOUNDS. |
YU52403A (en) | 2000-12-26 | 2006-03-03 | Dr.Reddy's Research Foundation | Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them |
US7160912B2 (en) | 2000-12-26 | 2007-01-09 | Dr.Reddy's Laboratories Ltd. | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them |
CA2405532A1 (en) | 2001-02-07 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods |
GB0108794D0 (en) * | 2001-04-07 | 2001-05-30 | Astrazeneca Ab | Chemical compound |
GB0108764D0 (en) * | 2001-04-07 | 2001-05-30 | Astrazeneca Ab | Chemical compounds |
EP1385844B1 (en) * | 2001-04-07 | 2006-07-05 | Astrazeneca AB | Oxazolidinones containing a sulfonimid group as antibiotics |
GB0108793D0 (en) * | 2001-04-07 | 2001-05-30 | Astrazeneca Ab | Chemical compounds |
WO2002085865A1 (en) * | 2001-04-20 | 2002-10-31 | Pharmacia & Upjohn Company | A method for the preparation of oxazolidinones |
ES2186550B2 (en) | 2001-06-27 | 2003-11-16 | Vita Lab | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIALS. |
CA2453182A1 (en) * | 2001-07-10 | 2003-01-23 | Meredith L. Greene | Crystalline thiazine oxazolidinones |
IL151012A0 (en) | 2001-08-03 | 2003-02-12 | Ribosomes Structure And Protei | Ribosomes structure and protein synthesis inhibitors |
US6952650B2 (en) | 2001-08-03 | 2005-10-04 | Yale University | Modulators of ribosomal function and identification thereof |
ES2288607T3 (en) | 2002-01-24 | 2008-01-16 | PHARMACIA & UPJOHN COMPANY LLC | DIHYDROTIAZINE AND ANTIMICROBIAL OXAZOLIDINON DIHYDROTIOPIRANE. |
AR038536A1 (en) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES |
US7141588B2 (en) | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
WO2003072576A2 (en) | 2002-02-28 | 2003-09-04 | Astrazeneca Ab | Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them |
WO2003072575A1 (en) | 2002-02-28 | 2003-09-04 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
AU2003224345A1 (en) * | 2002-04-30 | 2003-11-17 | Orchid Chemicals & Pharmaceuticals | Antibacterial agents |
WO2004014897A1 (en) | 2002-08-12 | 2004-02-19 | Pharmacia & Upjohn Company Llc | N-aryl-2-oxazolidinones and their derivatives |
WO2004026848A1 (en) | 2002-09-20 | 2004-04-01 | Lupin Limited | Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents |
US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US6875784B2 (en) | 2002-10-09 | 2005-04-05 | Pharmacia & Upjohn Company | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives |
KR100490643B1 (en) * | 2002-10-29 | 2005-05-19 | 한국과학기술연구원 | Novel methylidene piperidinyl oxazolidinone derivatives and preparation method thereof |
AR042086A1 (en) | 2002-11-21 | 2005-06-08 | Upjohn Co | N-ARIL-2- OXAZOLIDINON -5- CARBOXAMIDS AND THEIR DERIVATIVES, USED AS ANTIBACTERIAL AGENTS |
US7012088B2 (en) | 2003-02-24 | 2006-03-14 | Pharmacia & Upjohn Company | Indolone oxazolidinones and derivatives thereof |
BRPI0409217A (en) | 2003-04-09 | 2006-03-28 | Pharmacia & Upjohn Co Llc | antimicrobial derivatives and analogues of [3.1.0] bicycloexylphenyloxazolidinone |
JP4256744B2 (en) * | 2003-08-14 | 2009-04-22 | 三菱レイヨン株式会社 | Method for producing (meth) acrylic polymer |
US7687627B2 (en) * | 2003-09-08 | 2010-03-30 | Wockhardt Limited | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy |
US7304050B2 (en) | 2003-09-16 | 2007-12-04 | Pfizer Inc. | Antibacterial agents |
ES2803516T3 (en) | 2003-10-16 | 2021-01-27 | Symed Labs Ltd | A crystalline form of linezolid |
KR100854211B1 (en) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | Novel oxazolidinone derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same for antibiotics |
JP5383037B2 (en) | 2004-02-27 | 2014-01-08 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | Macrocyclic compounds and methods of making and using them |
WO2005099353A2 (en) * | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
WO2005113520A1 (en) * | 2004-05-20 | 2005-12-01 | Pharmacia & Upjohn Company Llc | Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents |
US20060142283A1 (en) * | 2004-06-29 | 2006-06-29 | Judith Aronhime | Crystalline form IV of linezolid |
US7429661B2 (en) | 2004-07-20 | 2008-09-30 | Symed Labs Limited | Intermediates for linezolid and related compounds |
WO2006091731A2 (en) * | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of linezolid intermediate |
US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
EP1899331B1 (en) | 2005-06-29 | 2009-11-25 | Pharmacia & Upjohn Company LLC | Homomorpholine oxazolidinones as antibacterial agents |
US20070197529A1 (en) * | 2005-12-01 | 2007-08-23 | Viviana Braude | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
EP2181994B1 (en) | 2006-03-31 | 2014-05-28 | Research Foundation Itsuu Laboratory | Antimicrobial compounds |
JP2009538933A (en) | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | Compounds and their use as cannabinoid receptor ligands |
BRPI0712720A2 (en) | 2006-05-31 | 2012-11-20 | Abbott Lab | thiazide compounds as cannabinoid receptor ligands and uses thereof |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
JP2010522760A (en) | 2007-03-28 | 2010-07-08 | アボット・ラボラトリーズ | 1,3-thiazole-2 (3H) -ylidene compounds as cannabinoid receptor ligands |
US8501794B2 (en) | 2007-04-17 | 2013-08-06 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
CA2683086A1 (en) | 2007-05-18 | 2008-11-18 | Abbott Laboratories | Color tunable light source |
EP2033960A3 (en) | 2007-09-04 | 2009-04-29 | Dipharma Francis S.r.l. | Linezolid crystalline hydrate form and linezolid salts |
US20090093631A1 (en) * | 2007-09-06 | 2009-04-09 | Ben-Zion Dolitzky | Processes for the preparation of a linezolid intermediate, linezolid hydroxide |
EP2208729A4 (en) | 2007-10-02 | 2011-04-27 | Res Found Itsuu Lab | Oxazolidinone derivative having 7-membered hetero ring |
WO2009063505A2 (en) * | 2007-10-08 | 2009-05-22 | Usv Limited | Process for preparation of (s) (n-[[3-[3-fluoro-4-(4-morpholinyl) hen l -2-oxo-5-oxazolidin l methyl]acetamide |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
ITMI20072359A1 (en) | 2007-12-18 | 2009-06-19 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF BONE DERIVATIVES |
WO2009114566A1 (en) | 2008-03-11 | 2009-09-17 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
MX2010010773A (en) | 2008-04-01 | 2011-04-11 | Abbott Gmbh & Co Kg | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy. |
CN102131811A (en) | 2008-06-24 | 2011-07-20 | 财团法人乙卯研究所 | Oxazolidinone derivative having fused ring |
CN102123993A (en) | 2008-08-15 | 2011-07-13 | 雅培制药有限公司 | Imine derivatives as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2163547A1 (en) | 2008-09-16 | 2010-03-17 | Unión Químico Farmacéutica, S.A. (UQUIFA) | Process for the preparation of an oxazolidinone antibacterial agent and intermediates thereof |
CA2737199A1 (en) | 2008-09-16 | 2010-03-25 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
KR101023174B1 (en) * | 2008-09-24 | 2011-03-18 | 주식회사 레고켐 바이오사이언스 | Novel Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and Pharmaceutical Compositions thereof |
NZ592717A (en) | 2008-10-07 | 2013-03-28 | Mpex Pharmaceuticals Inc | Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation |
SI2346509T1 (en) | 2008-10-07 | 2020-08-31 | Horizon Orphan Llc | Inhalation of levofloxacin for reducing lung inflammation |
KR101674146B1 (en) | 2008-10-10 | 2016-11-08 | 머크 샤프 앤드 돔 코포레이션 | Methods for preparing oxazolidinones and compositions containing them |
MX2011004090A (en) | 2008-10-17 | 2011-05-31 | Abbott Lab | Trpv1 antagonists. |
TW201020236A (en) | 2008-10-17 | 2010-06-01 | Abbott Lab | TRPV1 antagonists |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (en) | 2008-12-04 | 2015-04-10 | APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES | |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
SI2376480T1 (en) | 2008-12-05 | 2016-10-28 | Abbvie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
PA8854001A1 (en) | 2008-12-16 | 2010-07-27 | Abbott Lab | NEW COMPOUNDS AS CANABINOID RECEIVERS LIGANDS |
CN101774978B (en) | 2009-01-13 | 2011-09-21 | 联化科技股份有限公司 | Preparation method of linezolid and intermediate thereof |
JP5613176B2 (en) | 2009-01-19 | 2014-10-22 | アッヴィ・インコーポレイテッド | Apoptosis inducer for the treatment of cancer and immune and autoimmune diseases |
MX2011007684A (en) | 2009-01-19 | 2011-08-08 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases. |
CA2751392C (en) | 2009-02-03 | 2017-03-28 | Trius Therapeutics, Inc. | Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
AR075442A1 (en) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY |
TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
TWI519530B (en) | 2009-02-20 | 2016-02-01 | 艾伯維德國有限及兩合公司 | Carboxamide compounds and their use as calpain inhibitors |
WO2010111574A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
EP2411370B1 (en) | 2009-03-27 | 2015-04-22 | AbbVie Inc. | Compounds as cannabinoid receptor ligands |
EP2411382A1 (en) | 2009-03-27 | 2012-02-01 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8507493B2 (en) | 2009-04-20 | 2013-08-13 | Abbvie Inc. | Amide and amidine derivatives and uses thereof |
US8236798B2 (en) | 2009-05-07 | 2012-08-07 | Abbott Gmbh & Co. Kg | Carboxamide compounds and their use as calpain inhibitors |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
KR20190086591A (en) | 2009-05-26 | 2019-07-22 | 애브비 아일랜드 언리미티드 컴퍼니 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8580767B2 (en) | 2009-05-28 | 2013-11-12 | Trius Therapeutics, Inc. | Oxazolidinone containing dimer compounds, compositions and methods to make and use |
US8962639B2 (en) | 2009-05-29 | 2015-02-24 | Abbvie Inc. | Potassium channel modulators |
RU2563809C2 (en) | 2009-09-04 | 2015-09-20 | Мпекс Фармасьютикалс, Инк. | Using levofloxacin in aerosol form for treating mucoviscidosis |
WO2011029460A1 (en) * | 2009-09-09 | 2011-03-17 | Synthon B.V. | Nonhygroscopic linezolid salts |
WO2011050826A1 (en) | 2009-10-28 | 2011-05-05 | Synthon B.V. | Process for making crystalline form a of linezolid |
WO2011053740A1 (en) | 2009-10-28 | 2011-05-05 | Belkin International, Inc. | Portable multi-media communication device protective carrier and method of manufacture therefor |
CA2778266A1 (en) | 2009-11-25 | 2011-06-03 | Abbott Laboratories | Potassium channel modulators |
TW201130855A (en) | 2009-12-16 | 2011-09-16 | Abbott Lab | Prodrug compounds useful as cannabinoid ligands |
DK2550258T3 (en) | 2010-03-25 | 2015-12-07 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI520960B (en) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8586596B2 (en) | 2010-06-15 | 2013-11-19 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2603490A4 (en) | 2010-08-10 | 2014-01-01 | Abbvie Inc | Novel trpv3 modulators |
EP2690100A1 (en) | 2010-08-11 | 2014-01-29 | Synhton B.V. | Process for making linezolid |
CN103140487A (en) | 2010-08-11 | 2013-06-05 | 斯索恩有限公司 | Process for making linezolid |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
CA2810954A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
UA113500C2 (en) | 2010-10-29 | 2017-02-10 | MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | |
KR102095698B1 (en) | 2010-10-29 | 2020-04-01 | 애브비 인코포레이티드 | Solid dispersions containing an apoptosis-inducing agent |
WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
EP2640704A1 (en) | 2010-11-15 | 2013-09-25 | Abbvie Inc. | Nampt inhibitors |
SG10202010119TA (en) | 2010-11-15 | 2020-11-27 | Abbvie Inc | NAMPT And Rock Inhibitors |
WO2012067824A1 (en) | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Potassium channel modulators |
WO2012067822A1 (en) | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators |
HUE031267T2 (en) | 2010-11-23 | 2017-06-28 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
EP2643322B1 (en) | 2010-11-23 | 2017-08-30 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
KR101264903B1 (en) * | 2010-11-24 | 2013-05-15 | 한국과학기술연구원 | Oxazolidinone derivatives containing 2-pyrrolidone group or pharmaceutically acceptable salts thereof, and preparation method thereof |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
CN102617500B (en) * | 2011-01-31 | 2016-07-13 | 山东信立泰药业有限公司 | A kind of preparation method of linezolid intermediate, its preparation method and Linezolid |
WO2012104874A2 (en) * | 2011-02-02 | 2012-08-09 | Mylan Laboratories Limited. | Aqueous concentrated formulation of linezolid |
WO2012119653A1 (en) | 2011-03-09 | 2012-09-13 | Synthon Bv | Process for making crystalline form a of linezolid |
US8802693B1 (en) | 2011-03-09 | 2014-08-12 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
US9012651B2 (en) | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
UY33966A (en) | 2011-03-25 | 2012-10-31 | Abbott Lab | VANILLOID POTENTIAL TRANSITORY RECEIVER ANTAGONISTS 1 (TRPV1) |
CN102229577A (en) * | 2011-05-11 | 2011-11-02 | 石药集团中诺药业(石家庄)有限公司 | Method for preparation and purification of Linezolid intermediate |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8859549B2 (en) | 2011-05-13 | 2014-10-14 | Abbvie, Inc. | Potassium channel modulators |
KR101271224B1 (en) | 2011-07-05 | 2013-06-10 | 한국과학기술연구원 | Oxazolidinone derivatives containing new bicyclic group, having antibacterial activity, and preparation method thereof |
US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2013072923A1 (en) | 2011-09-19 | 2013-05-23 | Cadila Healthcare Limited | Process for the preparation of crystalline linezolid |
JP6162704B2 (en) * | 2011-10-11 | 2017-07-12 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | Sila analogs of oxazolidinone derivatives and their synthesis |
TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI571466B (en) | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
JP2014530911A (en) | 2011-10-24 | 2014-11-20 | アッヴィ・インコーポレイテッド | Methanol derivatives as TRPV3 modulators |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
MX2014006004A (en) | 2011-11-18 | 2015-04-16 | Abbvie Deutschland | N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy. |
WO2013096223A1 (en) | 2011-12-19 | 2013-06-27 | Abbvie Inc. | Trpv1 antagonists |
US8969325B2 (en) | 2011-12-19 | 2015-03-03 | Abbvie Inc. | TRPV1 antagonists |
EP2852580A1 (en) * | 2012-01-24 | 2015-04-01 | Jubilant Life Sciences Ltd. | Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2013120496A1 (en) | 2012-02-14 | 2013-08-22 | Pharmathen S.A. | Process for the preparation of linezolid in crystalline form and salts thereof |
CN103254148B (en) | 2012-02-15 | 2016-04-13 | 浙江海正药业股份有限公司 | The preparation method of linezolid intermediate |
WO2013149376A1 (en) | 2012-04-02 | 2013-10-10 | Abbott Laboratories | Chemokine receptor antagonists |
CN102643251B (en) * | 2012-04-17 | 2016-08-10 | 四川美大康佳乐药业有限公司 | degradation impurity of linezolid and preparation method thereof |
JP5989229B2 (en) | 2012-04-20 | 2016-09-07 | アッヴィ・インコーポレイテッド | Isoindolone derivatives |
CN102702125B (en) * | 2012-05-10 | 2014-09-03 | 浙江工业大学 | Chemical synthesis method for linezolid |
AU2013259344A1 (en) | 2012-05-11 | 2014-11-13 | Abbvie Inc. | Nampt inhibitors |
WO2013170118A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Thiazolecarboxamide derivatives for use as nampt inhibitors |
CA2873075A1 (en) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
CN104583194A (en) | 2012-05-11 | 2015-04-29 | 艾伯维公司 | Pyridazine and pyridine derivatives as NAMPT inhibitors |
US20130317055A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
US20130317054A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Neuronal nicotinic agonist and methods of use |
CN104364240B (en) * | 2012-06-08 | 2017-02-22 | 四川贝力克生物技术有限责任公司 | Drug for preventing or treating mycobacterial diseases |
WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
CN103570639B (en) * | 2012-08-08 | 2016-02-03 | 成都国弘医药有限公司 | A kind of synthetic method of Linezolid |
US20140080813A1 (en) | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
CN104995191A (en) | 2012-09-14 | 2015-10-21 | 艾伯维德国有限责任两合公司 | Tricyclic quinoline and quinoxaline derivatives |
WO2014071990A1 (en) | 2012-11-09 | 2014-05-15 | Synthon Bv | Process for making linezolid |
CN103896963B (en) * | 2012-12-26 | 2017-06-09 | 中国科学院上海药物研究所 | Ben Bing Evil Qin oxazolidinone compounds and its production and use |
WO2014118809A1 (en) | 2013-01-29 | 2014-08-07 | Actavis Group Ptc Ehf. | Pharmaceutical composition with linezolid |
US9650358B2 (en) | 2013-03-13 | 2017-05-16 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
CA2901929A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
CA2903538A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
UY35419A (en) | 2013-03-14 | 2014-10-31 | Abbvie Inc | PIRROLO KINASA CDK9 INHIBITORS (2,3- B) PIRIDINE |
AU2014230745A1 (en) | 2013-03-14 | 2015-09-03 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10A |
AU2014230747A1 (en) | 2013-03-14 | 2015-09-10 | AbbVie Deutschland GmbH & Co. KG | Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP2970264A1 (en) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
CN105992764A (en) | 2013-10-17 | 2016-10-05 | 艾伯维德国有限责任两合公司 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
CA2924699A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
IN2013MU03508A (en) | 2013-11-06 | 2015-07-24 | Unimark Remedies Ltd | |
ES2699001T3 (en) * | 2013-11-08 | 2019-02-06 | Lee Pharma Ltd | New oxazolidinone antibacterial compound |
WO2015068171A1 (en) * | 2013-11-08 | 2015-05-14 | Lee Pharma Limited | Novel oxazolidinone compounds |
US9840495B2 (en) | 2013-12-20 | 2017-12-12 | AbbVie Deutschland GmbH & Co. KG | Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases |
US9328112B2 (en) | 2014-02-06 | 2016-05-03 | Abbvie Inc. | Tetracyclic CDK9 kinase inhibitors |
EP3143023B1 (en) | 2014-05-15 | 2018-04-11 | AbbVie Deutschland GmbH & Co. KG | Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases |
US9617226B2 (en) | 2014-09-05 | 2017-04-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
US20180243298A1 (en) | 2015-04-02 | 2018-08-30 | Abbvie Inc. | Trpv3 modulators |
CA2990260A1 (en) * | 2015-07-17 | 2017-01-26 | The Global Alliance For Tb Drug Development, Inc. | Substituted phenyloxazolidinones for antimicrobial therapy |
KR101660874B1 (en) | 2015-09-04 | 2016-09-30 | 주식회사 알에스텍 | A Process for preparing linezolid and its intermediate |
WO2017066964A1 (en) | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
EP3636651A1 (en) | 2015-11-25 | 2020-04-15 | AbbVie Deutschland GmbH & Co. KG | Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders |
US10995097B2 (en) * | 2016-03-11 | 2021-05-04 | The Board Of Trustees Of The University Of Illinois | Small molecules active against gram-negative bacteria |
MX2018013573A (en) | 2016-05-07 | 2019-08-01 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors. |
EP3544965A4 (en) | 2016-11-28 | 2020-05-20 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase |
EP3601255A1 (en) | 2017-03-21 | 2020-02-05 | AbbVie Deutschland GmbH & Co. KG | Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical |
EP4119560B1 (en) | 2017-04-18 | 2024-06-05 | Fochon Pharmaceuticals, Ltd. | Apoptosis-inducing agents |
WO2018237140A1 (en) | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The University Of Illinois | Topoisomerase inhibitors with antibacterial and antcancer activity |
MX2020009586A (en) | 2018-03-14 | 2020-10-05 | Fochon Biosciences Ltd | SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS. |
CN112771025B (en) | 2018-03-23 | 2024-02-27 | 重庆复创医药研究有限公司 | Deuterated compounds as ROCK inhibitors |
CN108997247A (en) * | 2018-08-10 | 2018-12-14 | 泰州申合泰尔生物医药有限公司 | A kind of preparation method of Rivaroxaban intermediate |
CN112409286B (en) | 2019-08-20 | 2022-08-05 | 杭州迪克科技有限公司 | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone |
CN114957232B (en) * | 2021-05-28 | 2023-06-30 | 四川大学 | Benzodihydro oxazine compound, preparation method thereof and anti-tuberculosis application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54160371A (en) * | 1978-06-02 | 1979-12-19 | Kyowa Hakko Kogyo Co Ltd | Novel piperidine derivative and hypotensive agents comprising it |
ES8506659A1 (en) * | 1983-06-07 | 1985-08-01 | Du Pont | Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents. |
CA1260948A (en) * | 1984-12-05 | 1989-09-26 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents |
US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
ATE146783T1 (en) * | 1991-11-01 | 1997-01-15 | Upjohn Co | SUBSTITUTED ARYL AND HETEROARYL PHENYLOXAZOLIDINONES |
SK283420B6 (en) * | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials |
-
1994
- 1994-08-13 MY MYPI94002115A patent/MY115155A/en unknown
- 1994-08-16 ES ES94925765T patent/ES2139093T3/en not_active Expired - Lifetime
- 1994-08-16 DE DE10299007C patent/DE10299007I2/en active Active
- 1994-08-16 WO PCT/US1994/008904 patent/WO1995007271A1/en active Search and Examination
- 1994-08-16 AT AT94925765T patent/ATE185804T1/en active
- 1994-08-16 NZ NZ271805A patent/NZ271805A/en not_active IP Right Cessation
- 1994-08-16 SI SI9430287T patent/SI0717738T1/en unknown
- 1994-08-16 CN CN94193313A patent/CN1057087C/en not_active Expired - Lifetime
- 1994-08-16 DK DK94925765T patent/DK0717738T3/en active
- 1994-08-16 JP JP50866595A patent/JP3176630B2/en not_active Expired - Lifetime
- 1994-08-16 DE DE69421285T patent/DE69421285T2/en not_active Expired - Lifetime
- 1994-08-16 CA CA002168560A patent/CA2168560C/en not_active Expired - Lifetime
- 1994-08-16 EP EP94925765A patent/EP0717738B1/en not_active Expired - Lifetime
- 1994-08-16 KR KR1019960701191A patent/KR100301269B1/en not_active IP Right Cessation
- 1994-08-16 AU AU75570/94A patent/AU687866B2/en not_active Expired
- 1994-08-16 TW TW083107479A patent/TW293817B/zh not_active IP Right Cessation
- 1994-08-22 PH PH48830A patent/PH31634A/en unknown
- 1994-08-29 IL IL11080294A patent/IL110802A/en not_active IP Right Cessation
-
1999
- 1999-11-10 GR GR990402902T patent/GR3031809T3/en unknown
-
2000
- 2000-10-20 LV LVP-00-142A patent/LV12605B/en unknown
-
2002
- 2002-01-24 NL NL300079C patent/NL300079I1/en unknown
Also Published As
Publication number | Publication date |
---|---|
NL300079I1 (en) | 2002-04-02 |
KR960704866A (en) | 1996-10-09 |
LV12605A (en) | 2001-01-20 |
DE10299007I2 (en) | 2008-09-18 |
ES2139093T3 (en) | 2000-02-01 |
JPH09502436A (en) | 1997-03-11 |
CA2168560A1 (en) | 1995-03-16 |
DE10299007I1 (en) | 2002-07-04 |
TW293817B (en) | 1996-12-21 |
ATE185804T1 (en) | 1999-11-15 |
CN1057087C (en) | 2000-10-04 |
KR100301269B1 (en) | 2001-10-22 |
EP0717738A1 (en) | 1996-06-26 |
GR3031809T3 (en) | 2000-02-29 |
MY115155A (en) | 2003-04-30 |
AU687866B2 (en) | 1998-03-05 |
DE69421285T2 (en) | 2000-02-24 |
DE69421285D1 (en) | 1999-11-25 |
PH31634A (en) | 1999-01-12 |
EP0717738B1 (en) | 1999-10-20 |
CN1130379A (en) | 1996-09-04 |
WO1995007271A1 (en) | 1995-03-16 |
IL110802A (en) | 2000-09-28 |
LV12605B (en) | 2001-05-20 |
SI0717738T1 (en) | 2000-02-29 |
DK0717738T3 (en) | 2000-05-08 |
JP3176630B2 (en) | 2001-06-18 |
NZ271805A (en) | 1998-02-26 |
IL110802A0 (en) | 1994-11-11 |
AU7557094A (en) | 1995-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2168560C (en) | Substituted oxazine and thiazine oxazolidinone antimicrobials | |
US5688792A (en) | Substituted oxazine and thiazine oxazolidinone antimicrobials | |
US5547950A (en) | Oxazolidinone antimicrobials containing substituted diazine moieties | |
US5565571A (en) | Substituted aryl- and heteroaryl-phenyloxazolidinones | |
KR100312903B1 (en) | Esters of Substituted-Hydroxyacetylpiperazinephenyloxazolidinones | |
EP1987025B1 (en) | Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents | |
US20010047004A1 (en) | Oxazolidinone thioamides with piperazine amide substituents | |
ZA200109384B (en) | Bicyclic Oxazolidinones as antibacterial agent. | |
CA2614105A1 (en) | Oxazolidinone carboxamides containing azetidine and cyclobutane as antibacterial agents | |
WO2007004049A1 (en) | Oxazolidinones containing azetidine as antibacterial agents | |
US20090149520A1 (en) | Oxazolidinones containing oxindoles as antibacterial agents | |
WO2007004032A1 (en) | Oxazolidiones containing cyclobutane as antibacterial agents | |
US6348459B1 (en) | Sultam and sultone derived oxazolidinones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140818 |